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Chapter 1 
 
 
Introduction 
 
 
 
  
 
Introduction 
 
The discovery of antibiotics as antibacterial agents marks a turning point in the history of 
human health and literarily revolutionized modern medicine. For the past sixty-eight years, 
the use of antibiotic drugs has turned once life-taking bacterial infections into treatable 
diseases. With the commercialization of penicillin in 1941 and the rapidly increasing 
number of newly isolated microbial metabolites having similar antibacterial properties, a 
general definition was apparently required. In 1947, after much discussion, Waksman1 
realized that the widespread term ‘antibiotic’ in the sense first implied by himself and his 
collaborators evoked some philological discussion. He therefore advised amending the 
earlier definition as follows: “An antibiotic is a chemical substance, produced by micro-
organisms, which has the capacity to inhibit the growth of and even to destroy bacteria and 
other micro-organisms. The action of an antibiotic against micro-organisms is selective in 
nature, some organisms being affected and others not at all or only to a limited degree; each 
antibiotic is thus characterized by a specific antimicrobial spectrum. The selective action of 
an antibiotic is also manifested against microbial versus host cells. Antibiotics vary greatly 
in their physical and chemical properties and in their toxicity to animals. Because of these 
characteristics, some antibiotics have remarkable chemotherapeutic potentialities and can 
be used for the control of various microbial infections in man and in animals.” 
 
Since the introduction of penicillin pharmaceutical companies have produced more than 
160 antibacterial agents to combat the wide variety of bacterial infections2. Physicians 
today depend on antibiotics to treat many illnesses caused by bacteria, from rather simple 
ear and skin infections to more complicated and serious ones such as pneumonia, 
tuberculosis, polio, scarlet fever, meningitis, and other life-threatening infections. 
Moreover, antibiotics have become crucial in treating infections that result from medical 
procedures such as surgery, chemotherapy and transplantations, procedures that are 
widespread in modern society.  
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Figure 1 Glycopeptide A40926 and biotransformation to deacyl-A40926 by Actinoplanes 
teichomyceticus cells 
 
Glycopeptides are one of the major classes of antibiotics together with β-lactams (as 
penicillins and cephalosporins), aminoglycosides, tetracyclines, sulfonamides, macrolides 
(such as erythromycin) and quinolones. They are a family of compounds of natural origin 
demonstrating a strong activity against Gram-positive aerobic and anaerobic bacteria3. 
Typically they are large hydrophilic molecules with molecular masses between approximately 
1150 and 2200 Daltons (depending upon the presence or absence of acyl residues and sugars 
moieties, and on the type of aliphatic and/or aromatic amino acids). A prominent member of 
the glycopeptide family is A40926 (Fig.1). It demonstrates the high structural complexity 
of these molecules but also susceptibility to selective deacylation by Actynoplanes 
teichomyceticus cells, a main topic of this thesis research (see last paragraph). The two best 
known and until today still the only glycopeptide antibiotics commercially available for human 
use are vancomycin and teicoplanin. Other clinically relevant members of this important class 
of antibiotics are dalbavancin, oritavancin and telavancin, all semi-synthetic derivatives of 
natural glycopeptides. Dalbavancin is derived from A40926, oritavancin is obtained from 
chloroeremomycin, while telavancin is a semi-synthetic derivative of vancomycin. They are all 
currently in different stages of development. The FDA issued approvable letters for telavancin 
and dalbavancin in late 2007, and accepted a New Drug Application for oritavancin in early 
2008 4. Glycopeptides are often referred to as drugs of last resort against serious hospital 
infections caused by multidrug-resistant Gram-positive pathogens, particularly Methicillin-
12 
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resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CoNS; the 
coagulase test is used to differentiate Staphylococcus aureus (coagulase-positive) from 
other staphylococci) and enterococci. The great success of vancomycin and teicoplanin are 
mainly due to efficacy and absence of cross-resistance with other antibiotics (cross-resistance 
is the tolerance to an antibiotic as a result of exposure to a similarly acting substance), 
reflecting the unique mode of action of glycopeptides 5. Unlike β-lactams and all other 
inhibitors of the biosynthesis of the bacterial cell wall, glycopeptides act by the mechanism 
of selectively binding to the terminal D-Ala-D-Ala containing precursor of peptidoglycan 
(a polymer consisting of sugars and amino acids that forms a layer outside the plasma 
membrane of bacteria, forming the cell wall) 6. 
 
 
Figure 2 - Mechanisms of action of glycopeptide antibiotics (adapted from Nicolaou et al.6). 
Vancomycin binds to D-Ala-D-Ala, but is unable to bind to the cytoplasmic membrane and is poorly 
dimerized. By contrast, A40926 with its acyl chain is directly anchored to the membrane and is also a 
dimer former. These cooperative effects at the target site greatly enhance the activity of A40926. 
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Basically, transpeptidation and transglycosylation reactions, and consequently cross-linking 
and polymerization, that are essential for cell wall synthesis, are prevented by the formation 
of the complex between glycopeptides and bacterial muramyl stem peptides of growing 
peptidoglycan chains (Figure 2). 
 
Over the years the emergence of bacterial resistance to antibiotics has been observed as a 
general phenomenon7. The extensive use and misuse of antibiotics (such as taking an 
antibiotic for an inappropriate condition, in particular the use of antibiotics for viral 
infections, or not taking the entire course of the antibiotic, usually because the patient feels 
better before the infection is cured) has provided powerful pressure towards selection of 
resistant microbes. As a consequence, bacteria have mutated or have acquired new genes 
that allowed them to overcome the action of many antibiotics8. Until the mid 1980’s, 
resistance to glycopeptides was rarely observed. However, in 1987 first cases of resistance to 
vancomycin and teicoplanin were registered in strains of Enterococcus faecalis and 
Enterococcus faecium 9. Resistance is mediated by either of two gene clusters, vanA or vanB, 
and it is now widespread among these bacterial species. VanB enterococci are resistant only to 
vancomycin, while VanA enterococci are highly resistant to both glycopeptides10. The 
therapeutic options for severe infections caused by VanA enterococci are still quite limited, 
resulting in high mortality rates among infected patients. Even though this is considered a 
serious clinical problem, of a much greater concern is a transfer of the resistance from 
enterococci to highly virulent MRSA strains and a constant increase in the number of MRSA 
infections in the hospital 11 and community environment 12. Resistance to glycopeptides in 
MRSA first emerged in Japan in the late 1990’s in the form of strains that show reduced 
susceptibility to vancomycin (named later vancomycin-intermediate S. aureus or VISA), or 
both vancomycin and teicoplanin (named glycopeptides-intermediate S. aureus or GISA)13. 
Due to their moderate resistance to glycopeptides, combination therapy with other antibiotics is 
often needed to treat VISA and especially GISA infections. During the last decade 
glycopeptides-intermediate S. aureus strains have been isolated in numerous countries, 
particularly from patients having received prolonged therapy. More recently, in different 
hospital institutions in the United States, 6 new MRSA strains with high levels of resistance to 
14 
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vancomycin and teicoplanin have been reported 14. Striking feature is that those cases were 
vanA-mediated infections, suggesting that they have acquired the corresponding set of genes 
from enterococci. Widespread of such strains in hospital environments is undoubtedly an 
alarming scenario. Continuous spreading of bacterial resistance in enterococci and 
staphylococci towards the existing glycopeptide antibiotics became a major concern for the 
public healthcare authorities 15. This resulted in an ever-increasing clinical need for new 
and more potent anti-microbial agents with the challenge to achieve improved activity 
against multi- resistant S. aureus and enterococci 16. 
 
In a quest of better drugs against MRSA, research efforts carried out by Biosearch Italia (a 
former Italian company where all of the research presented in this thesis was carried out), 
resulted in the discovery of A40926, a prominent member of the glycopeptide antibiotic 
family structurally closely related to teicoplanin17. A40926 is a commercially very 
important molecule as it is the precursor for the semi-synthesis of dalbavancin, a novel 
glycopeptide agent, today a Pfizer Inc. proprietary drug. Dalbavancin is more potent than 
vancomycin and teicoplanin, and, while sharing many of their positive characteristics it 
lacks many of their weaknesses. It is highly active against coagulase-negative streptococci 
and MRSA that are poorly susceptible to teicoplanin. It is also highly active against all 
streptococci and non-VanA enterococci that are poorly susceptible to vancomycin 18. In 
addition, it shows high and prolonged plasma levels (suggesting easier administration and 
more favorable pharmacokinetics) 19. Dalbavancin displays strong synergy in vitro against 
VanA enterococci when tested in combination with Ampicillin (a β-lactam antibiotic used 
extensively to treat bacterial infections)20. It is also active against GISA and shows 
synergistic activity against GISA isolates in combination with β-lactam antibiotics 21. Due 
to all these positive characteristics, it is considered a second-generation glycopeptide. It 
combines: 1) the excellent in vivo efficacy, 2) very good safety profile, 3) ease of 
administration, and 4) improved potency against multi-resistant S. aureus and enterococci.  
 
Dalbavancin development was a very successful result of a much broader research program 
at Biosearch Italia to generate improved glycopeptides. An integral part of this research was 
15 
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the approach to structurally modify A40926. For that the deacylation of A40926 was 
studied as a starting point to generate a precursor for chemical derivatization. Since 
attempts of chemical deacylation resulted in extensive side-reactions, a biotransformation 
route was considered. A large screening program of microorganisms revealed that certain 
actinomycetes belonging to the Actinoplanes genus selectively cleave the fatty acid side 
chain of the molecule (see Fig.1) to yield the deacylated glycopeptide nucleus22. This 
derivative can then selectively be reacylated with different acyl chains or functional groups 
to generate novel compounds with improved antimicrobial activity. Also, deacyl-A40926 
was an indispensable element in structure-activity relationships (SAR) studies carried out 
under the same program. Among the strains selected during the screening program, 
Actinoplanes teichomyceticus was found to be the most efficient in deacylating A40926 22. 
Preliminary characterization of A. teichomyceticus deacylase described it as an endoenzyme 
associated with membrane integrity23 and the development of a whole cell 
biotransformation process was proposed.  
16 
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Aim and thesis outline 
 
A40926 is a glycopeptide antibiotic complex. It is a mixture of several structurally very 
closely related factors that differ only in the type of the fatty acid moiety linked to the 
aminoglucuronic acid unit of the molecule. The aim of this thesis research was to develop a 
lab-scale prototype for continuous deacylation of A40926 by immobilized cells of 
Actinoplanes teichomyceticus and to get insight into the origin of structural differences 
related to the fatty acid moiety of the molecule.  
 
The first step in our research work was to evaluate the feasibility of deacylation by 
immobilized cells. To this end we immobilized mycelium of Actinoplanes teichomyceticus 
in calcium-alginate gel beads and confronted their performance to suspended cells in a 
batch and repeated batch fashion (Chapter 2). We observed that immobilized cells can 
deacylate A40926 evenly well as suspended cells. Moreover, in repeated batch experiments 
deacylation was successfully maintained for more than a month, suggesting that a 
continuous process is also practicable. In this phase of the work we also introduced a 
method of co-immobilization with soybean meal, as an innovative mode of in situ supply of 
nutrient, and found that it improves deacylation capability of immobilized mycelium.  
 
In order to design any process based on an immobilized biocatalyst, effective diffusion 
coefficients of the substrate and of the product inside the immobilization matrix are 
essential. In Chapter 3 we describe determination of effective diffusion coefficients of 
A40926 and its deacylated derivative. These parameters were necessary for simulation 
calculations and were subsequently used in modeling of the continuous process in a single 
airlift bioreactor (Chapter 4) and in a cascade of three airlift bioreactors (Chapter 5). 
 
In addition to the effective diffusion coefficients, kinetic parameters are crucial values for 
examination of any biocatalytic process. The first part of Chapter 4 is dedicated to the 
determination of the deacylation kinetic parameters. We describe the deacylation by a 
Michaelis-Menten kinetic model and determined Vmax and Km values that were needed for 
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further studies. In the second part of Chapter 4 we address the continuous deacylation in a 
single lab-scale airlift bioreactor (ALR). The performance of a continuously operated ALR 
is evaluated by the model describing simultaneous diffusion and reaction in the biocatalyst 
beads. The ALR was operated continuously for 3 weeks with a constant conversion 
maintained above 60%, indicating good system stability. The experimental results agree 
well with the model estimates and the applicability of the proposed model for the design of 
a continuous deacylation process is thus demonstrated.  
 
Because of the very high costs of A40926 (the substrate for deacylation) and the high purity 
of the final product (deacyl-A40926) needed, a high overall conversion of ≥ 99% is 
required. By model simulations it was estimated that in a single continuous ALR such a 
high conversion could be achieved only at very long and impracticable residence times. 
This called for an alternative and operationally viable solution. Consequently, we examined 
and simulated other bioreactor operational modes. Considering diffusion and kinetic 
parameters, demonstrated stability of the system and quite high conversion (>60%) 
obtained in a single ALR, a possible solution was found in a cascade of airlift bioreactors. 
In Chapter 5 we describe the deacylation in a series of three perfectly mixed airlift 
bioreactors. A continuously operated cascade was designed using a model for a series of 
reactors with immobilized biocatalyst beads obeying Michaelis-Menten kinetics. The 
cascade system was operated continuously for almost two months and the model estimates 
for reactor volumes and relative conversions were found to be in good agreement with the 
experimental results. Under the operational regime implemented, a desired overall 
conversion of 99% was achieved, demonstrating the feasibility of the continuous 
deacylation process in a cascade configuration of 3 ALRs.  
 
A40926 is a complex mixture consisting of several structurally related factors. They differ 
in the structure of the acyl chain (Fig.1), subject of deacylation. In Chapter 6 we describe 
the origin of structural differences of the single components and demonstrate that the 
A40926 antibiotic complex composition closely reflects the fatty acid pattern present in the 
cell membrane of the producing microorganism. This finding is of particular value since it 
18 
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indicates the possibility of selectively changing the composition of the A40926 complex by 
altering the distribution of cell fatty acids (through addition of suitable precursors, like 
amino acids). Moreover, it suggests that new derivatives might be obtained by 
supplementing the fermentation medium with fatty carbons acids bearing desired structural 
features. The possibility to selectively direct biosynthesis of the A40926 acyl chain to the 
desired structure is very attractive as it offers a powerful tool to modulate (and eventually 
enhance) the binding capacity of A40926 derivatives to the membrane. That could lead to 
target-oriented production of novel and more active A40926 derivatives. 
 
Chapter 7 places this thesis in a broader context of the long lasting battle of man against 
multi-resistant bacteria and highlights some of the recent developments in a never-ending 
quest of better drugs against MRSA. 
 
19 
Charter 1 
References 
 
 
1. Waksman, S.A., 1947. What Is an Antibiotic or an Antibiotic Substance? Mycologia 39, 565-
569 
 
2. Service, R.F., 1995. Antibiotics that resist resistance. Science, 270, 724-727. 
 
3. Goldstein, E.J.C., Citron, D.M., Warren, Y.A., Tyrrell, K.L., Merriam, C.V., Fernandez, H.T. 
2006. In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and 
Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot Infections. Antimicrobial 
Agents and Chemotherapy, Vol. 50, No. 8, p. 2875-2879. 
 
4.  Abbanat, D., Morrow, B., Bush, K. 2008. New agents in development for the treatment of 
bacterial infections. Current Opinion in Pharmacology 8 (5), 582-592. 
 
5. Malabarba, A., Ciabatti, R. 2001. Glycopeptide derivatives. Current Medicinal Chemistry, 8 , 
1759-1773. 
 
6. Nicolaou, K.C., Boddy, C.N.C., Bräse, S., Winssinger, N. 1999. Chemistry, biology, and 
medicine of the glycopeptide antibiotics. Angew. Chem.-Int. Edit. 38, 2096-2152 
 
7. Gold, H.S., Moellering, R.C. 1996. Antimicrobial-drug resistance. Drug Therapy 35 (19), 
1445-1453. 
 
8. Taubes, G. 2008. The bacteria fight back. Science, 321, 356-361 
 
9. Uttley, A.H., Collins, C.H., Naidoo, J., George, R.C. 1988. Vancomycin-resistant enterococci. 
Lancet, 1, 57–58. 
 
10. Allen, N.E., Nicas, T.I. 2003. Mechanism of action of oritavancin and related glycopeptide 
antibiotics. FEMS Microbiology Reviews, 26, 511-532 
 
11. Kuehnert MJ, Hill HA, Kupronis BA, Tokars JI, Solomon SL, Jernigan DB. 2005. 
Methicillin-resistant–Staphylococcus aureus Hospitalizations, United States. Emerg Infect Dis  
11 (6), 868-872. 
 
12. Rybak, M.J., LaPlante, K.L. 2005. Community Associated Methicillin-Resistant 
Staphylococus Aureus: A Review. Pharmacotherapy 25 (1), 74-85. 
 
13. Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T., Tenover, F.C. 1997. Methicillin-
resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J 
Antimicrob Chemother. 40, 135-136. 
 
14. Dawn M. Sievert, D.M., Rudrik, J.T., Patel, J.B., McDonald, C.L., Wilkins, M.J., Hageman, 
J.C. 2008. Vancomycin resistant Staphylococcus aureus in the United States, 2002–2006. J 
Infect Dis, 46, 668–74. 
 
20 
Introduction 
21 
15. Willems, R.J.L., Top, J., van Santen, M., Robinson, D.A., Coque, T.M., Baquero, F., 
Grundmann, H., Bonten, M.J.M. 2005. Global spread of vancomycin-resistant Enterococcus 
faecium from distinct nosocomial genetic complex. Emerg Infect Dis 11 (6), 821-828. 
 
16. Payne, D.J. 2008.  Desperately seeking new antibiotics. Science 321, 1644-1645 
 
17. Parenti, F., Cavalleri, B. 1990. Novel glycopeptide antibiotics of the dalbaheptide group. 
Drugs of the future, 15 (1), 57-72. 
 
18. Van Bambeke, F. 2004.Glycopeptides in clinical development: pharmacological profile and 
clinical perspectives. Current Opinion in Pharmacology 4 (5), 471-478. 
 
19. Woodford, N. 2003. Novel agents for the treatment of resistant Gram-positive infections. 
Expert Opin. Investing. Drugs, 12 (2), 117-137. 
 
20. Jones, R.N., Biedenbach, D.J., Johnson, D.M., Pfaller, M.A. 2001. In vitro evaluation of BI 
397, a novel glycopeptide antimicrobial agent. J Chemother. 13 (3), 244-54. 
 
21. Biedenbach, D.J., Bell, J.M., Sader, H.S., Turnidge, J.D., Jones, R.N. 2009. Activities of 
Dalbavancin against a Worldwide Collection of 81,673 Gram-Positive Bacterial Isolates. 
Antimicrobial Agents and Chemotherapy, Vol. 53, No. 3, 1260-1263. 
 
22. Borghi, A., Spreafico, F., Beretta, G., Ferrari, P., Goldstein, B.P., Berti, M., Denaro, M., 
Selva, E. 1996 Deacylation of the Glycopeptide Antibiotic A40926 by Actinoplanes 
teichomyceticus ATCC 31121. J of Antibiotics, 49, 607-609 
 
23. Carrelli, A., Borghi, A., Carrano, L., Gastaldo, L., and Marinelli, F. 1995. Biotransformation 
of the lipoglycopeptide antibiotic A40926 by Actinoplanes teichomyceticus cells. Journal of 
Industrial Microbiology, 15, 429-433 
 
 

This chapter has been published as: Jovetić, S., Tramper, J., Marinelli, F. 1998. Biotransformation of the 
lypoglycopeptide antibiotic A40926 with immobilized cells of Actinoplanes teichomyceticus - In situ supply of 
nutrients. Enzyme and Microbial Technology, 22, 117-121. 
  
 
 
 
 
Chapter 2 
 
 
Biotransformation of the lipoglycopeptide 
antibiotic A40926 with immobilized cells of 
Actinoplanes teichomyceticus – 
 in situ supply of nutrients 
 
 
 
 

Biotransformation of A40926 with immobilized cells of Actinoplanes teichomyceticus 
Summary 
 
Mycelium of Actinoplanes teichomyceticus ATCC 31121 was immobilized or co-
immobilized with soybean meal in calcium-alginate beads. Immobilized mycelium was 
used to deacylate A40926 antibiotic complex in a batch and repeated-batch system and the 
results were compared with the performance of a suspension culture as well as washed 
mycelium. The specific deacylation rate of suspended cells was 0.19 mg g-1 h-1, while that 
of washed and immobilized mycelium was found to be much higher, i.e. 0.62 and 0.67 mg 
g-1 h-1, respectively. Biotransformation with suspended mycelium proved not to be 
attractive, in a repeated-batch system. After 8 days, i.e. two batch cycles, only 40% of the 
initial biomass was recovered, with a decrease in specific deacylation rate of 50%. In 
contrast to that, repeated-batch biotransformation with immobilized mycelium could be 
successfully maintained for longer than 30 days. During the first 15 days of operation, i.e. 
three batch cycles, the deacylation rates were rather constant, but gradually decreased after 
the third consecutive batch cycle. Co-immobilization with soybean meal as an in situ 
nutrient source improves deacylation capability of immobilized mycelium. 
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Introduction 
 
Biotransformation is increasingly exploited as a useful and often unique reaction step in the 
semi-synthesis of pharmaceuticals, or for structural modifications of complex natural 
compounds such as antibiotics 1 . Compound A40926 is a lipoglycopeptide antibiotic with a 
strong inhibitory activity against Gram-positive bacteria and Neisseria gonorrhoea 2 . It is 
produced by fermentation of Actinomadura ATCC 39727 as a complex of two main and 
five minor components. Individual components of the complex have an identical 
glycopeptide core but differ in the acid chains attached to the amino group of the 
glucuronic moiety 3. Actinoplanes teichomyceticus ATCC 31121 can deacylate A40926 as 
well as tert-butoxycarbonyl (tert-BOC) A40926, yielding the glycopeptide nucleus, which 
can be then synthetically reacylated to form new analogs (tert-BOC A40926 is a protected 
derivative of A40926, in which the amino group at C15 is blocked to prevent formation of 
diacyl analogs during reacylation) 4. A. teichomyceticus is a filamentous microorganism 
belonging to a rare genus of actinomycetes, previously discovered as the producer of 
teicoplanin antibiotic. 
 
In a previous study cells in suspension were used to deacylate A40926 tert-BOC 5. A batch 
process was developed and scaled up to 300 L, giving an average deacylation yield of 93 
%. With the objective of using the biomass more efficiently and repeatedly, and envisaging 
the development of a continuous deacylation process, cell immobilization was considered. 
There are many possible advantages of immobilized cell systems, including re-use of cells, 
facilitated recovery of products, and continuous operation with non-growing cells. It is also 
easily possible to apply different media, for instance first one optimal for cell growth and 
subsequently one optimal for biotransformation. In this paper deacylation of A40926 
tert-BOC with mycelium of Actinoplanes teichomyceticus immobilized in calcium-alginate 
beads is described. 
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Materials and Methods 
 
Chemicals 
 
A40926 tert-BOC and deacyl A40926 tert-BOC were prepared using di-tert-
butyldicarbonate (Janssen, Geel, Belgium) according to general procedures 6. Analytical 
reference substances of A40926 tert-BOC and deacyl A40926 tert-BOC were prepared in 
our laboratories and contained 867 mg/g and 894 mg/g of pure antibiotic respectively. The 
structure and the identity of the antibiotic complex have been determined using a 
combination of 1 H n.m.r. spectroscopy, fast atom bombardment mass spectrometry (FAB-
MS), chemical degradation and gas-chromatography mass spectrometry (GC-MS)3. 
Acetonitrile (Carlo Erba, Milan, Italy) was of HPLC grade, and all other reagents were of 
analytical grade unless otherwise indicated. 
 
Organism and Culture Conditions 
 
A. teichomyceticus ATCC 31121 was maintained in a frozen vegetative state in a cryovials 
at -80 °C. These stock cultures (working cell bank) were used as inocula (2.5% v/v) for 100 
ml preculture medium S/Bis (in g/L: glucose 10, bacto peptone 4, bacto yeast extract 4, 
MgSO4 x 7H2O 0.5, K2HPO4 4 ) in a 500 ml baffled Erlenmeyer flask. Preculture flasks 
were incubated for 72 h at 28 °C on a rotary shaker at 200 rpm. All experiments were 
carried out in baffled shake flasks with a foam stopper, with a liquid-to-air volume ratio of 
1:5, and at agitation rate of 200 rpm. Under these conditions Oxygen Transfer Rate was 
estimated to be around 20 mmol L-1 h-1 that was sufficiently high to avoid possible oxygen 
depletion. 
 
Method of immobilization 
 
A. teichomyceticus cells were immobilized in calcium alginate by a procedure similar to 
that previously described 7. Three ml of preculture mycelium suspension were mixed with 
57 ml of sterile 2.1 % sodium alginate (commercially available from Fluka Chemie AG; 
Fluka cat.no. 71238) at room temperature. Prior to immobilization sodium alginate was 
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sterilized by autoclaving for 15 minutes at 120°C (this procedure is routinely used in our 
laboratories and at Wageningen Agricultural University for sterilizing polysaccharides gels 
and was proven not to affect significantly the stability of the gel beads). In the case of co-
immobilization with soybean meal, 0.6 g of soybean meal was mixed with 57 ml of 2.1 % 
sodium alginate prior to sterilization. The mixture was extruded drop wise through the inner 
tube of an autoclaved steel dual nozzle (internal diameter 0.8 mm) into a sterile 0.2 M 
CaCl2 solution (large excess). The size of the drops was controlled by a coaxial, sterile, 
water-saturated airflow in the outer tube. The resulting beads were stirred in the CaCl2 
solution at room temperature for 2 h. After that beads were drained on an autoclaved steel 
sieve, washed with sterile water and immediately used for the pertinent experiments. All 
work was carried out in a laminar-air-flow cabinet. The diameter of the beads was 
measured using a Leitz Wetzlar stereoscope with micrometer ocular (10X magnification). 
The average bead diameter (dmean±SD) determined from a sample of 60 beads was 1.98 
±0.09 mm. 
 
Biotransformation with suspended cells 
 
500 ml baffled flasks containing 100 ml of AUR/M medium (in g/L: maltose 20, dextrin 
10, meat extract 4, yeast extract 2, peptone 4, soybean meal 15, CaCO3 2) were inoculated 
with 4 ml of preculture and incubated for 72 h at 28 °C on a rotary shaker at 200 rpm. After 
72 hours of growth, an amount of A40926 tert-BOC sodium salt, previously dissolved in 
sterile water at a concentration of 25 g/L, was added to the cultures, giving a final 
concentration of 0.4 g/L. Samples were collected every 24 hours to monitor the 
biotransformation reaction by HPLC analysis.  
 
Biotransformation with washed mycelium  
 
Whole culture or aliquots of 20 ml of a 72 h old AUR/M culture were washed twice with 20 
mM Tris-HCl buffer (pH 7.0) and resuspended in 100 ml Tris-HCl buffer in a 500 ml 
baffled flask. Substrate was added at a final concentration of 0.4 g/L and biotransformation 
followed daily by HPLC analysis. In a repeated-batch experiment a whole culture (100 ml) 
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was used and mycelium treated as described above. 
 
Biotransformation with immobilized mycelium 
 
Aliquots of 20 ml of the immobilized beads were incubated in 100 ml of AUR/M medium 
for 72 h at 28 °C on a rotary shaker at 200 rpm. After 72 hours of growth, beads were 
drained on an autoclaved steel sieve, washed with sterile water, and transferred to 500 ml 
baffled flasks containing sterile 20 mM Tris-HCl buffer (pH 7.0) with 0.4 g/L A40926 
tert-BOC (total volume of 100 ml). Biotransformation was monitored daily by HPLC. For 
repeated-batch deacylation the beads were, after each cycle, drained on a sieve, washed 
with sterile water, and transferred to a fresh buffer with 0.4 g/L A40926 tert-BOC. End 
volume of Ca-alginate beads plus liquid was always 100 ml. 
 
Sampling and experimental procedure 
 
Suspended cells and washed mycelium experiments 
 
Each sample point represents one shake flask (e.g. in Fig. 1 eight sample points represent 
eight parallel shake flasks, each one used for one single point in time). From each shake 
flask duplicate samples were drawn, and flask discarded. Two such experiments were 
carried out at different times using the same working cell bank, namely Working Cell Bank 
I. Values and error bars given in figures are average values ± SD.  
 
Repeated batch experiments with immobilized cells  
 
Two sets of experiments were carried out using two working cell banks, I and II 
respectively (see Fig.3a and b). Working Cell Bank I corresponds to a working cell bank 
used in the experiments with suspended cells and washed mycelium. Working Cell Bank II 
is prepared at a different time but from the same master cell bank. For each experiment two 
shake flasks were prepared using beads from the same batch of immobilization. At a 
sample point a single sample from each of two flasks was drawn. Values and error bars 
given in figures are average values ±SD. 
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Analyses 
 
Biomass measurements  
 
For the estimation of biomass dry weight in suspension, 10 ml samples of culture were 
vacuum filtered through a pre-dried, weighed Whatman No 1 filter paper, washed on the 
filter with 20 ml distilled water, and dried at 90 °C to constant weight. All measurements 
were done in duplicate. For the determination of mycelia dry weight immobilized in 
alginate beads, 50 beads were dissolved in 2% sodium-hexametaphosphate solution. The 
suspension was then filtered through a pre-dried, weighed Whatman No 1 filter paper and 
dried at 90 °C to a constant weight.  
 
HPLC analysis 
 
For a standard solution, a stock solution was prepared by dissolving analytical reference 
substance in 20 mM TRIS-HCl (pH 7) to obtain a concentration corresponding to 250 
mg/ml of pure antibiotic. When stored at 4 °C this solution was found to be stable for four 
months at least. In analysis the calibration standards were prepared by spiking 20 mM 
TRIS-HCl (pH 7) buffer with the stock solution to obtain a final concentration of 400 mg/L 
(external standard). 
 
For sample preparation and chromatographic condition, samples were collected and mixed 
with an equal amount of acetonitrile. After centrifugation (1200 x g for 10 minutes) the 
supernatant was injected for HPLC analysis. HPLC separations were done on a 5 μm 
Hewlett Packard ODS Hypersil column (4.6 x 100 mm) using a linear elution gradient from 
5% phase B (0.2% HCOONH4/CH3CN 3:7) in phase A (0.2% HCOONH4/CH3CN 9:1) to 
53% B in A in 35 min. The flow rate was 1.8 ml/min and the injection volume 30 μl. The 
column effluent was monitored at 254 nm. Linearity of this assay was r2 = 0.9986 in the 
working concentration range. 
 
A calculation of the concentration of antibiotics was determined by an external standard 
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procedure. The amount of A40926 tert-BOC and deacyl A40926 tert-BOC present in the 
sample was calculated as follows: 
 
] mg/L [   D*  
V*  A
V*  C*  A = ionconcentrat antibiotic
sstd
stds  
 
where As is the area of the peak of the antibiotic in the sample to be assayed, C is 
concentration [mg/L] of antibiotic in the analytical reference standard, Astd is the area of the 
peak of the antibiotic in the external standard, Vs is volume of the sample assayed, Vstd is 
volume of the external standard and D is the dilution factor. 
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Results and Discussion 
 
Biotransformations with suspended cells, and washed  
and immobilized mycelium 
 
The results of biotransformations with suspended cells, washed mycelium (whole culture 
and 20% of culture) and immobilized mycelium are given in Table 1. The whole culture of 
suspended cells transformed 80% of the initial substrate in 9 days, while washed mycelium 
(whole culture) convert 96% of the initial substrate in the same period (Figure 1).  
 
Table 1. Yields and deacylation rates of A.teichomyceticus  
 
 
Biomass 
(g L-1) 
Maximum 
deacylation rate 
(mg L-1 h-1) 
Maximum 
deacylation yield 
(%) 
Specific 
deacylation rate 
(mg g-1 h-1) 
Suspended cells 
(whole culture) 20.0 ±0.50 3.8 ±0.50 80 ±2 0.19 ±0.02 
Washed mycelium 
(whole culture) 19.0 ±0.49 5.0 ±0.48 96 ±2 0.26 ±0.03 
Washed mycelium 
(20% of culture) 4.2 ±0.12 2.6 ±0.23 70 ±1 0.62 ±0.06 
Immobilized cells 4.0 ±0.15 2.7 ±0.19 92 ±1 0.67 ±0.05 
 
Rates of accumulation of deacyl A40926 were maximal from day 1 to 2 (washed mycelium 
of whole culture) and from day 2 to 3 (suspended cells) of the experiments. From these data 
maximum volumetric deacylation rates (±SD) were calculated to be 3.8 ±0.50 and 5.0 
±0.48 mgL-1h-1 for suspended cells and washed mycelium, respectively. Consequently, the 
specific deacylation rates of suspended cells was 0.19 ±0.02 mgg-1h-1, which is a 30 % 
lower rate than that of washed mycelium. These findings confirm a previous premise that 
the fermentation broth contains competitive substrates and/or inhibitors of the deacylating 
enzyme and that removal favours the bioconversion 5. 
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Figure 1 Biotransformation of A40926 tert-BOC with washed mycelium of whole culture - ◊, and 
suspended cells - □, (error bars represent ±SD). 
 
With immobilized cells deacylation proceeded initially more slowly (Fig. 2). After one day 
of incubation with immobilized cells almost no deacyl product was detected while the 
substrate concentration in the liquid phase decreased as much as 30% (data not shown).  
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Figure 2 Biotransformation of A40926 tert-BOC with immobilized mycelium - □, and washed 
mycelium of 20 % of culture -◊; (error bars represent ±SD). 
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This suggests that during the first hours of incubation substrate diffusion into the gel 
matrices occurred, but with little concomitant deacylation. As the initially observed 
decrease in substrate concentration was higher than can be explained by the volume 
fraction of gel beads, it is probable that the partition coefficient of A40926-tert BOC in the 
gel phase is higher than one. Adsorption phenomena could be involved as well. The 
characteristics of the A. teichomyceticus deacylase are known to be similar to deacylase 
from other actinomycetes so far described in the literature 8 - 12. All those are endoenzymes, 
with a deacylating activity that is associated with membrane integrity. Thus, it is possible 
that some sort of temporary adsorption of the antibiotic onto the mycelium is taking place. 
Further investigations are under way to clarify these points.  After two days the reaction 
proceeded at a constant rate of 2.7±0.19 mgL-1h-1, reaching a more than 90 % conversion 
after 9 days (Fig. 2). The maximum deacylation yield and the specific deacylation rate of 
immobilized cells were found to be 92 ±1% and 0.67 ±0.05 mgg-1h-1, respectively. It is 
interesting to note that yield achieved with immobilized mycelium was much higher than 
the one found when the same amount of biomass (20 % of whole culture) was used as a 
washed mycelium (Table 1 and Fig. 2). These findings are probably explained by improved 
stability of the metabolic enzymes of immobilized cells. Similar observations have been 
reported by other authors 13,14. 
 
Repeated-batch deacylation with washed and immobilized mycelium 
 
Repeated-batch biotransformations were done with washed mycelium, immobilized 
mycelium and mycelium co-immobilized with soybean meal using two working cell banks 
(Figs. 3a and 3b). Mycelia were coimmobilized with 1% (w/v) soybean meal with the idea 
of providing immobilized cells of A. teichomyceticus with the in situ nutrient source. 
Soybean meal is an important component of the growth medium. It is used in the AUR/M 
medium formulation as a long-term slow-releasing source of nitrogen as well as 
carbohydrates. Previous experiments with various medium formulations in which soybean 
meal was substituted with other nutrients (e.g. Soytone) while giving a good mycelium 
growth failed to deliver a good deacylation capacity of biomass. Thus we postulated that 
soybean meal might be important for deacylation and that its in situ presence in beads 
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would facilitate this process in a certain way. Data obtained from the experiments with 
Working Cell Bank I support this premise (Table 2, Fig. 3a).  
 
Table 2. Deacylation rates with washed mycelium and immobilized mycelium in repeated-batch 
process (data corresponds to Fig. 3-a) 
 
Maximum volumetric deacylation rate ± SD (mg L-1 h-1)   
Batch cycles washed mycelium immobilized 
mycelium 
mycelium co-immobilized 
with soybean meal 
1 4.4 ± 0.23 2.3 ± 0.08 2.8 ± 0.15 
2 2.3 ± 0.17 2.6 ± 0.07 3.6 ± 0.07 
3 0.8 ± 0.09 2.0 ± 0.09 3.1 ± 0.09 
4 - 1.4 ± 0.05 1.8 ± 0.11 
5 - 0.9 ± 0.06 1.2 ± 0.04 
 
When the experiments were repeated with a new batch of the working cell bank, namely 
Working Cell Bank II (Fig. 3b), the same trends are observed confirming previous findings. 
At the end of each batch cycle, more deacylated antibiotic was produced with mycelium co-
immobilized with soybean meal than with mycelium immobilized without soybean meal.   
 
With washed mycelium the repeated-batch process proved not to be attractive. Volumetric 
deacylation rates decreased substantially with each new batch  (Table 2 and Fig. 3). This is 
primarily due to a low biomass recovery after each batch cycle. Only 40% of the initial 
biomass was recovered after two batch cycles (Fig. 4). Such a low biomass recovery 
resulted in a five times lower volumetric deacylation rate in the third batch as compared to 
the first one (Table 2). Nevertheless, the specific deacylation rate was constant during the 
first two cycles, 0.27 and 0.25 mgg-1h-1, respectively.  However, it decreased to about 50% 
in the third batch, suggesting major loss of catalytic activity. This could be explained by 
leakage of enzymes due to physical damage of mycelia. Repeated washing/centrifugation 
steps apparently pose high shear stress on cells, which in turn disturbs cell integrity.  
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Figure 3 Repeated-batch biotransformation of A40926 tert-BOC with washed mycelium of whole 
culture (◊), immobilized mycelia (∆), and mycelia co-immobilized with soybean meal (□). 
Error bars represent ± SD. Working Cell Bank I (a), Working Cell Bank II (b). 
 
In contrast to repeated-batch deacylation with washed mycelia, biotransformation with 
immobilized mycelia proved feasible and was successfully maintained for 30 days, during 
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five batch cycles (Fig.3). The volumetric deacylation rate was rather constant during the 
first three consecutive batches (Table 2).  
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Figure 4 Repeated-batch biotransformation with washed mycelium of whole culture (specific 
deacylation rate, open histogram; biomass concentration ∆) and mycelium co-immobilized 
with soybean meal  (specific deacylation rate, closed histogram; biomass concentration □). 
Error bars represent ± SD. Data related to experiments done with the Working ell Bank I. 
 
However, it decreased thereafter, probably due to loss of biocatalyst. This is explained by 
observed leakage of biomass from the gel matrix and rupture of some gel beads. The 
specific deacylation rate also decreased after the third batch cycle (Fig. 4), suggesting a 
certain degree of enzyme inactivation. Nevertheless, the specific deacylation rate of 
immobilized mycelium in the fifth batch was still about twice the rate of washed mycelium 
in the first batch. 
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Conclusions 
 
Actinoplanes teichomyceticus immobilized in Ca-alginate can be successfully used for 
deacylation of lipoglycopeptide antibiotic A40926 tert-BOC. Co-immobilization with 
soybean meal improves deacylation capability of immobilized mycelium and should be 
considered as a novel method for providing in situ nutrients. In a repeated-batch 
biotransformation process immobilized biomass can be effectively used for one month, 
during five consecutive batch cycles. Experiments are under way to study further 
deacylation of A40926 tert-BOC by immobilized mycelium, and will be subject of our next 
paper. 
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Chapter 3 
 
 
Diffusion of (de)acylated antibiotic A40926 in 
alginate and carrageenan beads with or without 
cells and/or soybean meal 
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(de)acylated antibiotic A40926 in alginate and carrageenan beads with or without cells and/or soybean meal. 
Enzyme and Microbial Technology, 28, 510-514. 

Diffusion of (de)acylated antibiotic A40926 in alginate and carrageenan beads  
Summary 
 
Effective diffusion coefficients (De) of antibiotic A40926 and its deacylated derivative were 
determined in Ca-alginate (2% wt/wt) and κ-carrageenan (2.6% wt/wt) gel beads with or 
without immobilized Actinoplanes teichomyceticus cells and/or soybean meal (SBM). The 
method used was based on transient concentration changes in a well-stirred antibiotic 
solution in which gel beads, initially free of solute, were suspended. Unsteady-state 
diffusion in a sphere was applied and De determined from the best fit of experimental data. 
A40926 showed markedly different diffusion characteristics than its deacylated derivative. 
Diffusivity of deacyl-A40926 in alginate or carrageenan gel beads was six to seven times 
that of A40926. Large differences in partition coefficients (Kp) were also found. In case of 
beads without additions, A40926, in contrast to deacyl-A40926, strongly partitioned to the 
liquid phase. Introduction of SBM and/or mycelium in the gel beads decreased the effective 
diffusivity of deacyl-A40926, but increased its partitioning to the solid phase. Our findings 
indicate that a relatively moderate structural change of a lipoglycopeptide molecule could 
lead to a major change in its diffusion/partition characteristics. 
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Introduction 
 
Entrapment in polysaccharide gels is one of the most commonly used techniques for 
immobilization of bacterial cells.1 This technique is widely accepted because it comprises a 
simple, mild and non-destructive procedure compatible with viable cells. The most 
frequently used gels are Ca-alginate and κ-carrageenan, in which case cells are normally 
immobilized in small spherical beads. In these beads cells can experience a different local 
environment than when freely suspended in medium. This difference is the result of mass 
transfer resistance and, in some cases, also due to solute partitioning between solid and 
liquid phase. Solute partitioning is commonly described by the partition coefficient (Kp), 
while mass transfer can be described by the external stagnant-film mass-transfer resistance 
and the internal mass-transfer resistance. Very often, hydrodynamic operative regimes 
applied in the bioprocesses are such that the external-film mass-transfer resistance is 
negligible with respect to the internal mass-transfer resistance. Internal mass transfer, i.e. 
transport of substrates and products inside the gel beads, occurs by diffusion and the 
effective diffusion coefficient (De) is the parameter that mathematically describes the rate 
of this transport per unit of driving force. Studies of internal mass transfer are thus a 
prerequisite for a good understanding and proper description of the immobilized biocatalyst 
system.  
 
The subject of our research is A40926, the proprietary lipoglycopeptide antibiotic of 
Biosearch Italia. In our laboratories we are currently developing BI397, a semisynthetic 
derivative of A40926. New and often more specific and more active analogs of this 
attractive antibiotic can be obtained by synthetic reacylation of its deacylated derivative. To 
this end A40926 is selectively deacylated by Actinoplanes teichomyceticus ATCC 31121 to 
yield the glycopeptide nucleus (Fig. 1). In our previous work we used immobilized 
A.teichomyceticus for deacylation of A40926.2 We demonstrated the feasibility of the 
immobilized biocatalyst system for this particular biotransformation and examined in situ 
supply of nutrients by co-immobilizing soybean meal in the gel beads. For modeling the  
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Figure 1 - Biotransformation of A40926 to deacyl-A40926 by Actinoplanes teichomyceticus 
ATCC 31121. 
 
process that will employ immobilized A. teichomyceticus, values of the effective diffusion 
coefficient for the substrate and the product are needed. The main objective of this work 
was to determine the diffusion characteristics of antibiotic A40926 and its deacylated 
derivative in Ca-alginate and κ-carrageenan gel beads.  
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Materials and Methods 
 
Preparation of gel beads 
Four different types of beads were used: gel beads without additions, gel beads with co-
immobilized soybean meal (SBM; 1% wt/wt), gel beads with entrapped mycelium of A. 
teichomyceticus, and gel beads with 1% SBM and entrapped mycelium. Ca-alginate beads 
were prepared by the procedure previously described.2 κ-carrageenan gel beads were 
prepared by the same immobilization technique. For that, a 2.6% (wt/wt) solution of κ-
carrageenan (Genugel X0828, A/S Kobenhavns Pektinfabrik, Lille Skensved, Denmark), 
with or without 1% (wt/wt) SBM, was extruded drop wise and beads collected in 0.75 M 
KCl at 5 °C. A layer of ice-cold n-decane was first brought upon the KCl solution to 
facilitate formation of spheres, as proposed by Buitelaar et al.3 n-Decane is known to be 
non-toxic to cells because of its high logP value4. The diameter of the beads was measured 
using a Leitz Wetzlar stereoscope with micrometer ocular (10X magnification). The typical 
average bead diameter (dmean±SD) determined from a sample of 100 beads was 2.44 ±0.09 
mm. To prepare gel beads with mycelium, aliquots of 20 ml of the beads with 4% inoculum 
(volume of vegetative culture / volume of gel) were incubated in 100 ml of AUR/M 
medium for 72 h at 28 °C on a rotary shaker at 200 rpm.2 After 72 hours of growth, beads 
were drained on an autoclaved steel sieve, washed with sterile water, and immediately used 
for the diffusion experiments. To estimate mycelial dry weight, 50 beads were dissolved in 
2% sodium-hexametaphosphate solution. The suspension was then filtered through a pre-
dried, weighed Whatman No 1 filter paper and dried at 90 °C to a constant weight. Amount 
of biomass was calculated to be 20 g per liter of gel. 
 
Diffusion experiments  
Diffusion experiments were conducted at 28 °C in a thermostatic room and in a closed 
vessel to avoid evaporation. All the solutions and the beads used were kept in the same 
room for at least 2 hours before the experiments were started. To start experiments a known 
volume of A40926 or deacyl - A40926 solution was placed in a closed cylindrical glass 
vessel.  The solution was agitated on a magnetic stirrer set at 700 rpm to avoid external 
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mass-transfer resistance. The significance of the external mass-transfer resistance can be 
evaluated by the Biot number, which is defined as the ratio of the external and internal 
mass-transfer resistance. Using the procedure described by van’t Riet and Tramper5 
external mass-transfer resistance was estimated. Considering effective diffusivities 
obtained, Bi was estimated to be > 74, under experimental conditions, indicating that 
external mass-transfer resistance could be neglected with respect to the internal mass-
transfer resistance.  
 
At time zero a known volume of beads was quickly dropped into the appropriate solution. 
The transient concentration change of the solute in the liquid phase was followed by HPLC 
analysis described elsewhere.2 The sum of the individual sample volumes taken for the 
HPLC analysis was in all experiments below 0.1 % of the liquid-phase volume.  
 
Diffusion-coefficient calculations 
The theoretical background for the determination of the effective diffusion coefficient is 
given by Crank.6 In this study we used method described by Wijffels et al.7 with 
modifications explained below. When spherical beads that are initially free of solute are 
suspended in a well-stirred solution with an initial solute concentration Cs,l 0, and provided 
that the external mass-transfer resistance surrounding the beads is negligible, the transient 
concentration change of the solute in liquid phase, Cs,l (t), is given by: 
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In Eq. (1), De is the effective diffusion coefficient, t is the diffusion time, R is the bead 
radius, and the qn's are positive non-zero roots of the transcendental equation: 
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α is the ratio of the volume of the solution, excluding the volume of the beads, to the 
volume of the beads divided by the partition coefficient and can be expressed as: 
 
  
α =  3 ⋅ lV
4 ⋅π ⋅ 3R ⋅ bn ⋅ pK     ( 3 ) 
 
where Vl is the volume of liquid phase, nb is the total number of beads and Kp is the 
partition coefficient. The partition coefficient Kp between the gel and the solution is defined 
as the solute concentration ratio in the beads and in the solution at equilibrium: 
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Equation (1) contains De and subsequent qi values as fitting parameters. A curve fitting 
procedure was applied to numerical solutions to equation (2). As a result, an explicit 
solution to qi = f (  α , i) was obtained (in which i stands for the ith solution): 
 
  qi = 0.064 + 3.107 ⋅ i + 0.361 α    ( 5 ) 
 
Substitution of equation (5) for i = 1..5 in equation (1) yielded an explicit expression for Cs,l 
= f (De,   α ) which was then used to fit data on Csl = f(t), yielding De and   α  values. The 
  α value was then used to calculate the partition coefficient Kp according to equation (3). 
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Results and Discussion 
 
Figure 2 shows an example of transient deacyl-A40926 concentration in the liquid phase. 
Antibiotic concentration in the solution decreased, and the equilibrium was reached after 
about one hour. Equation (1) adequately describes the data. It has been originally developed 
for a single sphere. Nevertheless, given the small variation in bead size, it can also be 
applied to a number of spherical beads using the average diameter of the beads. 
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Figure 2 - Diffusion of deacyl-A40926 into alginate beads without additions. Solid line corresponds 
to the best fit, dashed lines represent 99% confidence region. 
 
The results obtained with the different bead types are summarized in Table 1. In each case 
experiments were carried out twice and the values for the effective diffusion coefficient and 
the partition coefficient given are mean values. Diffusion characteristics of deacyl-A40926 
in gel beads of alginate and carrageenan without additions are similar considering the small 
difference in De. However, with alginate the compound tends to partition to the liquid 
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phase while with carrageenan the opposite was found.  
 
Table 1 - Effective diffusion and partition coefficient of A40926 and deacyl-A40926 in 2% Ca-
alginate and 2,6 % κ-carrageenan gel beads 
 
A40926 deacyl-A40926 
Bead type D e x 10 11 
[m2 s-1] 
K p 
[-] 
D e x 10 10 
[m2 s-1] 
K p 
[-] 
Alginate 2.86 0.17 2.11 0.87 
Alginate +SBM 0.39 16.32 1.41 1.70 
Alginate + mycelium 0.97 2.27 1.35 2.32 
Alginate +SBM + 
mycelium 0.53 10.60 1.05 3.38 
κ-Carrageenan 3.14 0.29 2.19 1.32 
κ-Carrageenan + SBM 0.59 20.01 1.57 1.78 
 
Introduction of SBM and/or mycelium in the gel beads decreases De, but at the same time 
increases partitioning to the solid phase. The decrease in De was to be expected since 
soybean meal and/or mycelium inside the gel matrix creates additional internal mass-
transfer resistance. Increase in partitioning coefficient towards the beads can be attributed 
to adsorption. Temporary adsorption of the antibiotic to soybean meal has been observed in 
previous experiments (unpublished results). 
 
Qualitative behavior of A40926 and deacyl-A40926 are similar considering diffusion in 
free gel beads (Figure 3). However, there are significant quantitative differences. In the gel 
beads without additions, De values of A40926 are an order of magnitude lower than those 
found for the deacyl-A40926. This difference might be attributed to the presence of the 
long hydrophobic acyl chain on the amino-sugar moiety. Much higher partitioning to the 
liquid phase was also found. These observations can be explained by the chemical 
characteristics of A40926. While deacyl-A40926 is present as a free molecule in the 
aqueous solution, A40926 tends to form pseudo-micelle structures8. This is mainly due to 
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the presence of the long hydrophobic acyl chain that could act as an apolar  “tail” of the 
polar glycopeptide “head”.  
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Figure 3 -  Diffusion of A40926 into alginate beads without additions. Solid line corresponds to the 
best fit, dashed lines represent 99% confidence region. 
 
When soybean meal and/or mycelium were immobilized in the gel beads, A40926 strongly 
partitions to the solid phase. Adsorption of A40926 to the soybean meal has been observed 
before, as mentioned above. In the case when mycelium was immobilized in the beads, the 
presence of biocatalyst requires that the reaction of deacylation should be considered as 
well. However, the reaction is known to have a long lag phase9 and the rate is at least an 
order of magnitude lower than the rate of diffusion in gel beads without additions 
(unpublished results). Moreover, deacyl-A40926 was not detectable in the liquid phase 
during the course of the experiments. Still, the presence of biocatalytically active mycelium 
in the gel beads undoubtedly influences mass transfer characteristics of this system. 
A.teichomyceticus deacylase, enzyme responsible for this biotransformation, is an 
endoenzyme whose deacylating activity is associated with membrane integrity.10-11 
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Considering the chemical structure of the substrate, it is likely that A40926 is temporary 
anchored to the membrane bilayer by its lipophilic acyl chain.8 This adhesion event can be 
seen as a prelude to the catalytical cleavage of the chain itself and is probably another 
reason why, when mycelium was present in the gel beads, A40926 partitions to the solid 
phase.  
 
 
Conclusions 
 
Unsteady-state diffusion in a sphere, as presented here, could be used for the determination 
of effective diffusion coefficients of antibiotic A40926 in Ca-alginate and κ-carrageenan 
gel beads. Lipoglycopeptide antibiotic A40926 showed markedly different 
diffusion/partition characteristics than its deacylated derivative. When soybean meal and/or 
A.teichomyceticus mycelium was present in the gel beads A40926 strongly partitions to the 
solid phase. For modeling and optimization of the deacylation process both diffusion 
characteristics of the system and kinetics of the immobilized mycelium are needed. Our 
current work is directed towards determination of deacylation kinetics and process 
description by the experimentally determined parameters. 
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Deacylation of A40926 by immobilized A. teichomyceticus in an internal-loop air-lift bioreactor 
Abstract 
 
A40926 is a natural glycopeptide antibiotic. It is a precursor of dalbavancin, a semi-
synthetic second-generation glycopeptide in clinical development for the treatment of β-
lactam-resistant Staphyloccous aureus and Staphylococcus epidermidis infections. 
Deacylation of A40926, producing an intermediate useful for the synthesis of novel 
derivatives, can be carried out by the action of Actinoplanes teichomyceticus cells. Kinetics 
parameters for this particular deacylation reaction were obtained by fitting the experimental 
data to a Michaelis-Menten kinetic model. The feasibility of A40926 deacylation by 
immobilized A. teichomyceticus cells in an air-lift bioreactor was examined. A single 
continuously operated air-lift reactor (ALR) was evaluated by a model describing diffusion 
and reaction in the biocatalyst beads. Model estimates were in a good agreement with 
experimental results.  The system was operated continuously for 21 days with overall 
conversion above 60%.  
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Introduction 
 
The subject of our research is A40926, the proprietary antibiotic of Biosearch Italia. 
A40926 is a natural glycopeptide produced by Nonomuria sp. ATCC 397271. It is a 
precursor for the semi-synthesis of dalbavancin, a novel second-generation glycopeptide 
agent belonging to the same class of drugs as vancomycin and teicoplanin. Formerly 
referred to as BI-397, dalbavancin is designed to be an improved alternative to those 
antibiotics2. In clinical studies to date, it appears to be a potent antibiotic for the treatment 
of infections by β-lactam-resistant Staphyloccous aureus and Staphylococcus epidermidis 
strains.  
 
Ever-increasing clinical need and importance of dalbavancin led to a quest for the new 
analogs of A40926. Screening microorganisms for the ability to transform this antibiotic, 
Actinoplanes teichomyceticus ATCC 31121 was found to selectively cleave the acyl group 
of A40926 (Fig. 1) and of its protected tert-BOC derivative3,4. The deacylated tert-BOC 
A40926 thus obtained represents an attractive intermediate, since deacyl tert-BOC A40926 
can be chemically reacylated with various side chains to yield new, putatively more specific 
and active analogs. Moreover, in-depth studies on the influence of aliphatic chain on the 
antibacterial activity of new analogs and their binding to the target bacterial structure are 
made possible. In our previous work we used suspended4 and immobilized5 
A.teichomyceticus cells for deacylation of A40926 tert-BOC. We demonstrated the 
feasibility of the repeated batch deacylation with immobilized biocatalyst and proposed a 
continuous process as an alternative to the batch process5. For the development and 
modeling of such a process, kinetic parameters of the biotransformation reaction have to be 
known. The objective of this work was to determine kinetic parameters and examine 
A40926 deacylation by immobilized A. teichomyceticus in a continuous process.  
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Figure 1 -  Biotransformation of A40926 to deacyl-A40926 by A. teichomyceticus ATCC 31121. 
 
In the present contribution an internal-loop air-lift reactor (ALR) was used. System was 
operated continuously for three weeks. Kinetic parameters were obtained by fitting 
experimental data to the Michaelis-Menten kinetic model while the theoretical development 
and the calculation procedures of De Gooijer et al.6 were used as a tool to describe 
continuous deacylation of A40926 by immobilized biocatalyst. This model described the 
simultaneous diffusion and conversion of substrate in the biocatalyst beads with or without 
external-diffusion limitation. Kinetic constants, substrate diffusion coefficient7 and other 
operational parameters were used as input for the model simulations. Calculated estimates 
were in a good agreement with experimental results.  
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Materials and Methods 
 
Chemicals 
 
A40926 tert-BOC and deacyl A40926 tert-BOC (in further text A40926 and deacyl 
A40926) were prepared as previously described5.  Acetonitrile (Carlo Erba, Milan, Italy) 
was of HPLC grade, and all other reagents were of analytical grade unless otherwise 
indicated. 
 
Organism and Culture Conditions 
 
Actinoplanes teichomyceticus ATCC 31121 was maintained in a frozen vegetative state at -
80 °C. The stock cultures were used as inoculums (2.5% v/v) for 100 ml pre-culture 
medium S/Bis (in g/l: glucose 10, bacto peptone 4, bacto yeast extract 4, MgSO4 x 7H2O 
0.5, K2HPO4 4) in a 500 ml baffled Erlenmeyer flask. Pre-culture flasks were grown for 72 
h at 28 °C on a rotary shaker at 200 rpm, and used as inoculums in subsequent experiments. 
For the kinetic experiments washed cells of A. teichomyceticus were prepared in the 
following way: 500 ml baffled shake flasks containing 100 ml of AUR/M medium (in g/l: 
maltose 20, dextrin 10, meat extract 4, yeast extract 2, peptone 4, soybean meal 15, CaCO3 
2) were inoculated with 4 ml of pre-culture and incubated at 28 °C on a rotary shaker at 200 
rpm. After 72 h of growth cultures were washed twice with 20 mM Tris-HCl buffer (pH 
7.0) and resuspended in 100 ml Tris-HCl buffer in a 500 ml shake flasks.  
 
Kinetic measurements 
 
For determination of kinetic parameters substrate conversion was measured as a function of 
time. In two independent experiments ten different initial substrate concentrations were 
used. A total of 22 shake flasks with washed cells of A. teichomyceticus  (as described 
above) were used for kinetic experiments and dry cell weight determinations. At t=0 h, 
different amounts of A40926 sodium salt, previously dissolved in sterile water at a 
concentration of 25 g/l, were added to each pair of shake flasks to yield desired initial 
substrate concentrations. The culture flasks were incubated at 28 °C on a rotary shaker at 
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200 rpm. Samples were collected at regular time intervals and analyzed by HPLC. All 
measurements were carried out in duplicate. The initial reaction rates were determined by 
linear regression. The reaction rates are expressed in mol deacyl-A40926 formed per kg dry 
cell weight per second. 
 
Kinetic calculations 
 
Previous studies suggest that the deacylation of A40926 by A. teichomyceticus cells can be 
described by Michaelis-Menten kinetics4. To determine kinetic parameters a simple 
Michaelis-Menten expression (Eq. 1) was used, 
sm
s
CK
C
VV +∗= max     ( 1 ) 
where V is the initial reaction rate  (mol g-1 h-1 ), Vmax is the maximum reaction rate  (mol g-
1 h-1 ), Cs is the substrate concentration (mol l-1) and Km is the Michaelis constant (mol l-1).  
Parameter estimation was done by fitting Eq. 1 to experimental data pairs of substrate 
concentrations versus initial reaction rates. TableCurve 2D, (Version 3 for Windows, Jandel 
Scientific) software was used for data fitting and statistical analysis. 
 
Method of immobilization 
 
Actinoplanes teichomyceticus cells were immobilized in calcium alginate gel by a 
procedure previously described 5. All work was carried out in a laminar-air-flow cabinet. 
The diameter of the beads was measured using a Leitz Wetzlar stereoscope with 
micrometer ocular (10X magnification). The average bead diameter (dmean±SD) determined 
from a sample of 120 beads was 2.05 ±0.11 mm. Beads with two gel loads, 53 and 28 kg of 
dry cell weight per m3 of gel respectively, were obtained and used in two ALR 
experiments. 
 
Analyses 
 
Concentration of biomass in a suspension and in the immobilized beads was estimated by 
dry weight measurements described elsewhere5. The concentration of A40926 and deacyl-
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A40926 was determined by an external standard procedure using analytical reference 
substances prepared in our laboratories. HPLC analytical method, sample preparation and 
calculation procedure used were previously described 5.  
 
ALR experiments  
 
The vessel used in this study was a glass made, internal-loop air-lift reactor (ALR) 
constructed by the glass workshop of Wageningen University (The Netherlands). The 
working volume of the reactor was 0.43 l  (a cross section of the ALR is given in Fig. 2).  
 
 
Substarte in 
Out
Air out 
Antifoam in 
Antifoam probe 
Air 
Baffles 
Sample port 
Water jacket 
 
 
Figure 2 - Cross section of internal loop Air-Lift Reactor. 
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The temperature in the reactor was kept constant at 28 °C by circulating water in the jacket. 
A Gilson Minipuls 2 peristaltic pump controlled incoming and outgoing liquid flow. To 
prevent excessive foaming a Bioengineering antifoam control system was applied with a 
silicone based antifoam agent. Aeration was executed by sterile air, supplied through the 
ceramic porous sparger at the bottom of the ALR at a flow rate of 0.21 l min-1. The ALR 
was operated continuously twice for 21 days. The inlet substrate concentration was 2.04 x 
10-1 mol m-3. The flow rates employed were 1.5 x 10-9 m3 s-1 in the first experimental run, 
and 2.5 x 10-9 m3 s-1 in the second experiment. In both experiments reactor gel hold-up was 
20 % (v/v). Biocatalyst gel load in the first experimental run was 53 kg m3 gel while in the 
second run 28 kg m3 gel was used. Beads were kept in the reactor by a Teflon sieve at the 
overflow of the ALR. Two samples of 1 ml were taken daily to monitor substrate and 
product concentration.  
 
Model input parameter values  
 
Initial and operational parameter values used for the model calculations were as follows: 
maximum substrate consumption rate, Vmax = 9.25 x 10-8 mol kg s-1; Michaelis–Menten 
constant, Km = 9.21 x 10-2 mol m-3; effective substrate diffusion coefficient, Deff = 9.7 x 10-
12 m2 s-1; mean bead diameter, d = 2.05 x 10-3 m; inlet substrate concentration, Csi = 2.04 x 
10-1 mol m-3; substrate feed rate = 1.5 x 10-9 m3 s-1 and 2.5 x 10-9 m3 s-1; reactor gel hold-up 
= 20 % (v/v); biocatalyst gel load = 28 kg  m-3 gel and 53 kg  m-3 gel; mass transfer 
coefficient in a liquid film around the beads, kl,s = 1.54x10-6 m s-1, zero-order decay rate, kd 
= 6.39 x 10-4  h-1. The steady-state measurements were taken after the ALR was operated 
continuously for 14 and 21 days. 
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Results and Discussion 
 
Kinetic parameters 
 
Kinetic experiments were carried out in shake flasks containing washed cells of A. 
teichomyceticus at a concentration of 20 g l-1 dry weight. Ten different initial 
concentrations (0.02 – 1 mM) of antibiotic A40926 were used in two independent 
experiments.  This was done intentionally in order to assure reproducibility and consistency 
of the data. The initial reaction rates were determined by linear regression and expressed as 
moles deacyl-A40926 formed per kg dry cell weight per second. The experimental data of 
A40926 concentrations vs. initial reaction rates from both experiments were fitted to the 
Michaelis-Menten equation. Figure 3 shows that there is a good agreement between the 
experimental data and the fitted curve.  In Michaelis-Menten kinetics, the estimation of Vmax 
and Km is rather poor if the experiments are carried out only at low concentrations ([S] << 
Km). It is therefore important to explore a wide range of concentrations. Our experimental 
data show that the substrate concentrations chosen for the kinetic experiments were 
appropriate, covering also the range where  [S] >> Km  (Fig.3).  
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Figure 3 - The initial reaction rates as a function of A40926 concentration for the Actinoplanes 
teichomyceticus catalyzed deacylation. The experimental data are fitted to a Michaelis-
Menten kinetic model (solid line corresponds to the best fit, dashed lines represent 95% 
confidence region) 
 
64 
Deacylation of A40926 by immobilized A. teichomyceticus in an internal-loop air-lift bioreactor 
The fitted model was found to explain 98 % (radj2) of the total variation. The estimated 
parameters are shown in Table I. These values were used as intrinsic parameters for A. 
teichomyceticus cells immobilized in Ca-alginate. 
 
Table I – Estimated kinetic constants for deacylation of A40926 by whole cells of Actinoplanes 
teichomyceticus 
 
Parameter Unit Value Min * Max  * 
Vmax ( mol kg s-1 ) 9.25 x 10-8 8.54 x 10-8 9.95 x 10-8 
Km ( mol m-3 ) 9.21 x 10-2 6.79 x 10-2 11.63 x 10-2 
 
* Min and max are 95% confidence limits for the parameter values 
 
A40926 deacylation in ALR 
 
Two experimental runs with ALR were carried out as described in Materials and Methods 
section. Conditions for two experiments were chosen in such a way that differences in 
estimated substrate bulk concentrations were large enough. In the first run higher 
biocatalyst gel load (53 kg m-3 gel) and lower feed rate (1.5 x 10-9 m3 s-1) were chosen. In 
the second experiment the opposite was the case, i.e. lower biocatalyst gel load (28 kg m-3 
gel) and higher feed rate (1.5 x 10-9 m3 s-1) were chosen. Figure 4 shows steady-state 
antibiotic concentration after 14 and 21 days, together with model calculations. The 
difference in steady-state concentrations for two experimental runs was shown to be 
statistically significant as there were no overlap of the 95% confidence regions. That 
allowed us to examine performance of the ALR as well as model predictions under 
operational conditions of low and high relative conversion. Clearly, higher biocatalyst gel 
load and lower feed rate (i.e. higher residence time) in experimental run I (Fig.4) resulted in 
lower substrate bulk concentration and consequently higher relative conversion.  
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Figure 4 - Substrate bulk concentrations in both experimental runs after 14 and 21 days of 
operation. Empty bars represent observed values (error bars give 95% confidence 
region).  Model estimates are given by cross-hatched bars (error bars give the range of 
estimates with (kl,s = 3.85x10-7 m s-1) and without film theory.  
 
Substrate and product concentration profiles observed during the experiments suggested 
progressive linear loss of biocatalyst activity in the reactor. To account for the loss of 
activity in time the inactivation rate was calculated as a zero-order process. The decay rate 
kd was estimated to be 6.39 x 10-4 h-1, which corresponds to the 19.3 % activity loss after 
two weeks at 28° C. For the model calculations shown in Figure 4, a correction of the 
maximal substrate conversion rate Vm was made using estimated inactivation rate. A 
number of days between start-up and steady-state measurement were taken into account.  
 
Model estimates were obtained using method of De Gooijer et al.6. This calculation 
procedure considers internal diffusion and reaction in the beads with or without external 
mass-transfer resistance. In the immobilized biocatalyst systems, like the one described 
here, external mass-transfer can play a significant role in the overall mass-transfer 
resistance. The importance of the external mass-transfer can be evaluated by the Biot 
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number (Bi), which is defined as the ratio of the mass transfer resistance in the stagnant 
liquid film around the bead to the internal resistance found in the bead8. We used the 
procedure described by van’t Riet and Tramper9 to estimate external mass-transfer 
resistance and considering the effective diffusion coefficient7, Biot number was calculated 
for given experimental conditions. The resulting value (Bi = 163) indicated that external 
mass-transfer resistance is negligible with respect to the internal mass-transfer resistance. 
Consequently, calculations were done excluding external mass-transfer resistance, and in 
order to give a range of model estimates using one quarter of the estimated value of kl,s = 
1.54x10-6 m s-1. Figure 4 clearly shows that calculated estimates agreed well with the 
observed values in both experimental runs. This suggests that the model could be employed 
as adequate predictor for the deacylation of A40926 by immobilized biocatalyst. 
 
Model simulations 
 
A proposed model was used to simulate continuous deacylation of A40926 in order to 
examine the range of experimental conditions. The influent substrate concentration chosen 
is given in Materials and Methods and was the one used in our previous work5. Bead 
diameter and the gel load values were the same as in two experiments while the flow rate 
(i.e. residence time) was chosen as a variable that can be easily modified. Other parameter 
values were as given in Materials and Methods. In Figure 5, model estimates are given for 
the relative conversion as a function of the residence time using two experimental 
biocatalyst gel loads, namely 28 kg m-3 gel (dashed line) and 53 kg m-3 gel (solid line).  
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Figure 5 - Model estimates for the conversion of A40926 in the ALR as a function of residence time 
(solid line – biocatalyst gel load = 53 kg m-3 gel, dashed line - biocatalyst gel load = 28 
kg m-3 gel). Experimental conversions are for run I (diamond symbol) and run II (square 
symbol). 
 
It is clear that biocatalyst gel load has a significant effect on the relative conversion (dashed 
line remains below solid one over the whole range of residence times).  This is more 
pronounced if shorter residence times are used. On the other hand, at increasing residence 
time, the conversion increases. Hence, a combination of parameters was examined in two 
experimental runs taking in consideration physical (i.e. biocatalyst gel load) and operational 
(i.e. residence time) limits of the system. Figure 5 shows the experimentally determined 
relative conversions of 19.5 and 60.9 % respectively. Clearly, increasing biocatalyst gel 
load and residence time concomitantly, a three fold higher conversion is obtained. The 
model estimates agree well with the experimental results of both experiments.  
 
If a continuous deacylation process is to be developed, competitive advantage should be 
demonstrated over the established batch process. One of the most important aspects of the 
process, considering very high cost of the substrate (i.e. antibiotic), is the final conversion. 
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Thus, overall conversion in a continuous process should exceed 93%, usually obtained in a 
batch system [4]. In a single ALR this could be achieved (theoretically) only at very long 
and from the operational point of view impracticable residence times. This makes 
continuous processes based on a single reactor rather unattractive. Nevertheless, our results 
are encouraging. Considering kinetic characteristics, stability of the system and rather high 
conversion (> 60%) obtained with a single ALR, a cascade of bioreactors, could prove very 
attractive alternative to the existing batch process. 
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Conclusions 
 
Continuous deacylation of A40926 by immobilized Actinoplanes teichomyceticus cells was 
evaluated in an air-lift loop-reactor. The deacylation kinetics were described by the 
Michaelis-Menten equation and kinetic parameters obtained. Using experimentally 
determined kinetic and diffusion7 parameters continuous deacylation was modelled 
applying procedures of De Gooijer et al.6. Inactivation of the biocatalyst as a function of 
time was observed during the experiments. Decay rate was found to be significant with 
respect to the duration of the experiments and was incorporated in the model calculations. 
System was operated continuously for three weeks with a constant conversion above 60%. 
Our current work is directed towards modelling and implementation of a series of ALR for 
the deacylation of A40926, and will be subject of our next paper. 
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Continuous biotransformation of A40926 in a cascade of three airlift bioreactors 
Abstract 
 
Immobilized cells of Actinoplanes teichomyceticus ATCC 31121 were used to selectively 
cleave the acyl group of A40926 yielding the deacylated form of the molecule. The 
feasibility of this particular biotransformation in a series of three perfectly mixed air-lift 
bioreactors with immobilized cells was examined. A continuously operated air-lift cascade 
was designed using a model for a series of reactors with immobilized biocatalyst beads 
obeying Michaelis-Menten kinetics. In independent experimental runs the cascade 
bioreactor system was operated continuously for 56 days with an overall conversion of 
99%. Model estimates for reactor volumes and relative conversions were found to be in a 
good agreement with the experimental results. 
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Introduction 
 
Glycopeptide antibiotics are a family of compounds of natural origin. They demonstrate a 
strong activity against Gram-positive aerobic and anaerobic bacteria and this led to the 
introduction into clinical practices of vancomycin and teicoplanin.  A40926 is another 
member of the glycopeptide antibiotic family, which was discovered in our laboratories1,2. 
It is produced by Nonomuraea sp. ATCC 39727 and it is the precursor for the semi-
synthesis of dalbavancin, a novel second-generation glycopeptide agent3. Dalbavancin is 
currently in Phase III of clinical studies and it appears to be a potent antibiotic for the 
treatment of patients infected with the difficult-to-treat strains of MRSA (methicillin-
resistant Staphyloccous aureus) and MRSE (methicillin-resistant Staphylococcus 
epidermidis)4,5. 
 
In recent years the rapid emergence of bacterial resistance to the existing glycopeptide 
antibiotics became an issue of great concern to public health and resulted in an ever-
increasing clinical need for new and more potent anti-microbial agents6. In an R&D 
program to generate new and more active analogs of A40926 pursued in our laboratories, 
biotransformation combined with chemical modifications was attempted7,8,9. The 
deacylated form of A40926 was proposed as an interesting molecule that can act as a 
starting point for the synthesis of novel structures. Deacylation of A40926 was successfully 
achieved with whole cells of Actinoplanes teichomyceticus ATTC 31121 and a batch 
process was developed10,11. As a further development, we examined the feasibility of using 
immobilized A.teichomyceticus cells for this particular biotransformation12. These results 
suggested that a continuous process with immobilized cells might be an interesting 
alternative to the established batch process. Consequently, the deacylation reaction was 
described with Michaelis-Menten equation, the kinetic parameters were determined, and a 
continuous processing with immobilized cells was attempted in a single airlift reactor 
(ALR)13. However, the high cost of the substrate (i.e. A40926) combined with a complex 
downstream process and final purification, demands for a process able to deliver a high 
conversion yield (> 95 %). In our continuous system based on a single reactor such a high 
conversion was never achieved and a series of bioreactors was suggested as an alternative. 
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Here we describe the design and the continuous deacylation in a cascade of three ALRs. To 
design a cascade the theoretical development and the calculation procedures of De Gooijer 
et al.14 were used. This model, based on the earlier work of Luyben and Tramper15, 
describes the simultaneous diffusion and conversion of substrate in the biocatalyst bead, 
giving an estimation of the substrate concentration profile in the bead. It is used in the 
design of perfectly mixed reactors in series, containing the immobilized biocatalyst obeying 
intrinsic Michaelis-Menten kinetics. In literature, the model was evaluated with 
immobilized enzymes and Bakker et al.16described sucrose conversion with immobilized 
invertase in a series of bioreactors. Here, for the first time the model was evaluated in a 
series of bioreactors with immobilized whole aerobic cells. From practical point of view a 
short, three-vessel cascade is well suited when aerobic systems are studied, so we employed 
that set-up in our experiments. In the present contribution we used the model for the 
predictions and previously determined M-M kinetic parameters13 and effective diffusion 
coefficients17 were used in the calculations. Model estimates for reactor volumes and 
relative conversions in ALRs were compared with experimental results and the overall 
performance of the cascade is discussed. 
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Materials and Methods 
 
Chemicals 
 
Substrate, A40926 tert-BOC and the deacylated product, deacyl A40926 tert-BOC (in 
further text A40926 and deacyl A40926) were prepared in our laboratories as previously 
described12.   
 
Organism, Culture Conditions, and Immobilization Method 
 
Actinoplanes teichomyceticus ATCC 31121 was maintained as a frozen vegetative stock at 
-80 °C and cultivated as described by Jovetić et al.13. Immobilization in 2% calcium 
alginate gel was carried out by a procedure previously described12. Two batches of beads 
were prepared with gel loads of 28 and 53 kg of dry cell weight per m3 of gel, respectively. 
Leitz Wetzlar stereoscope (10X magnification) was used to measure the diameter of the 
beads. From a sample of 150 beads the average bead diameter (dmean±SD) was determined. 
Values of 2.01±0.09 mm and 2.05±0.11 mm were found for the two batches of beads and 
used in model calculations.   
 
Analyses 
 
Substrate and product concentrations were determined by HPLC. Analytical method, 
sample preparation and calculation procedure used were as given by Jovetić et al.12.  
 
Cascade experiments  
 
A series of three equal-sized airlift reactors (ALR) was assembled (a schematic 
representation of the cascade is given in Fig.1).  
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Air bubble 
Sample Sample Sample 
 
 
Figure 1 - Cascade of three air-lift reactors (cross-section view) 
 
Internal diameter of each vessel was 0.04 m and liquid height 0.34 m. The working volume 
of each single reactor was 0.43 L, giving a total working volume of the cascade of 1.29 
liters. Operational temperature was 28 °C and airflow rate 0.21 L min-1. The substrate, 
antibiotic A40926, was dissolved in 20 mM Tris-HCl buffer (pH 7.0) and fed continuously. 
The inlet substrate concentration chosen was 2.04 x 10-1 mol m-3 as used also in our 
previous experiments of biotransformation12,13.  Reactor gel hold-up was 20 % (v/v), a 
value commonly used in heterogeneous biocatalysis. To choose appropriate residence times 
in the cascade, several preliminary experiments were executed using two batches of 
biocatalyst beads and different substrate flow rates. At this early stage model estimates for 
a wide range of flow rates (i.e. residence times) were used in order to facilitate choice of 
operational conditions. On the basis of model estimates and preliminary experimental runs 
two distinct operational regimes were chosen for evaluation, namely Run A and Run B. In 
both runs the cascade was operated continuously for 56 days. In Run A, the flow rate 
employed was 1.5 x 10-9 m3 s-1 and the biocatalyst gel load was 53 kg m-3 gel. In Run B, the 
flow rate was 2.5 x 10-9 m3 s-1 and the biocatalyst gel load was 28 kg m-3 gel. Duplicate 
samples of 1 ml bulk liquid were taken daily to monitor substrate and product 
concentration.  
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Model input parameters 
 
Parameter values used for the model calculations were as follows: maximum substrate 
consumption rate, Vmax = 9.25 x 10-8 mol kg s-1 and Michaelis–Menten constant, Km = 9.21 
x 10-2 mol m-3 13; effective substrate diffusion coefficient, Deff = 9.7 x 10-12 m2 s-1 17; mean 
bead diameter for the run A, dI = 2.01 x 10-3 m; mean bead diameter for the run B, dII = 2.05 
x 10-3 m; Inlet substrate concentration, Csi = 2.04 x 10-1 mol m-3; substrate feed rate FI= 1.5 
x 10-9 m3 s-1 (Run A) and FII=2.5 x 10-9  m3 s-1 (Run B); reactor gel hold-up ε = 20 % (v/v); 
biocatalyst gel load XI = 53 kg  m-3 gel (Run A) and XII=28 kg  m-3 gel (Run B);  first-order 
biocatalyst decay rate, kd = 5.4 x 10-3  d-1. 
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Results and Discussion 
 
Choosing the cascade 
 
In our previous work we studied a continuous deacylation in a single air-lift reactor13. 
Examining a range of conditions we managed to reach a maximum conversion of 61 %, 
quite distant from the at least 95 % needed. This was mainly due to the rather high M-M 
constant (Km) of deacylation13 and to the fact that we used only one continuous reactor. 
Theoretically, a higher conversion can be achieved in a single reactor, but requires a very 
long and operationally impracticable residence time.  To overcome this hurdle, a plug-flow 
mode of operation was contemplated. The main difficulty in operating a plug-flow reactor 
with immobilized aerobic cells is the need to supply oxygen. Thus, a cascade of airlift 
reactors was considered as an alternative. When several (N ≥ 3) perfectly mixed vessels are 
used in series, plug-flow behavior can be approximated. ALRs used in our studies were 
small-scale vessels (V < 1 l) having a regular aspect ratio (H/D < 9), thus behaving as 
ideally mixed reactors (see next section). Hence, a cascade of three internal-loop airlift 
reactors was assembled and implemented as an approximation of an aerated plug-flow 
bioreactor. 
 
Mixing in the cascade 
 
When a cascade of bioreactors is operated in a continuous fashion (as described here) the 
liquid residence time in each reactor should largely exceed the mixing time, in order to 
prevent short cut flow of substrate between the single reactors. To evaluate mixing in air-
lifts, the concept of characteristic times was introduced and Verlaan showed18 that for air-
lift loop reactors:  
 
  mixT = ( 4 to 7 ) × circT    ( 1 ) 
 
where Tmix is the characteristic mixing time of the liquid phase (s) and Tcirc is the 
characteristic liquid circulation time (s). Considering terminal rising velocity of the gas 
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bubbles in a liquid (approximately 0.25 m/s 19) and the small size of the reactors used in 
this study (liquid height of 0.34 m), characteristic circulation time was expected in the order 
of seconds. Thus, according to Eq. 1 the characteristic mixing time is estimated to be less 
than a minute. In the two experimental runs described here, the liquid residence times used 
were more than two orders of magnitude higher than the estimated mixing time, thus 
guaranteeing perfect mixing and no short-cut flows between reactors.  
 
Continuous A40926 deacylation 
 
A40926 is a very expensive substrate as it is used in biotransformation as highly purified 
antibiotic. Also downstream processing of the deacylated product is costly and greatly 
dependent on the degree of conversion. Because of these considerations, a main goal of the 
continuous deacylation process was to maximize substrate conversion, aiming at 99% or 
more. To achieve the desired conversion in a continuous biotransformation, substrate feed 
rate is often the parameter of choice that is easy to modify. In several pilot experiments 
with the cascade, different substrate flow rates were evaluated using two batches of 
biocatalyst beads. For each flow rate the relative conversions in the outflow of the cascade 
was determined after steady state was achieved. In Table I experimental conversions 
observed in these experiments are given. Clearly, residence times longer than 2 days are 
required for the 99% conversion to be achieved with a biocatalyst gel load of 53 kg of dry 
cell weight per m3 of gel.  
 
Table I – Experimental conversions of A40926 (expressed in %) in the outlet flow of the cascade as a 
function of residence time and two biocatalyst gel loads  
 
Biocatalyst gel load [ kg m-3 gel ] Residence time 
[days ] 
28 53 
1.3 39 62 
1.7 55 78 
2.1 61 85 
 
Besides a high conversion, a second objective of our work was model evaluation, and in 
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order to evaluate model predictions adequately two distinct operational regimes were 
required that will provide large enough differences in relative conversions. Moreover, 
employment of different biocatalyst gel loads was preferred as additional model parameter 
variations.  On the basis of these considerations and pilot experimental results, model 
calculations were used to set biocatalyst gel load and substrate feed rate parameter values 
for further experiments. Two different experimental conditions were chosen. High 
biocatalyst gel load / low substrate feed rate regime (Run A: 99 % theoretical conversion in 
model calculations) and low biocatalyst gel load / high substrate feed rate (Run B: 67 % 
theoretical conversion in model calculations). Under these conditions two 56-day runs, 
namely run A and run B, were executed as described in the Materials and Methods section. 
Figure 2 shows the experimental values of the relative conversions (expressed as the ratio 
of product concentration and inlet substrate concentration) in all three reactors during 
experimental run A. It can be seen that experimentally observed relative conversions in the 
outflow of the cascade were between 95 and 99 % throughout the experiment. This 
compares favourably to the established batch process where overall conversion achieved is 
usually ≤ 90% 11. Two weeks after the start of the experiment a progressive decrease in the 
relative conversions was observed suggesting a constant loss of catalytic activity. Usually 
such trend is described by first-order kinetics. Accordingly, the decay rate, kd, was 
estimated to be 5.4 x 10-3 d-1, and taken into account in the model calculations. After six 
weeks of continuous operation (day 42), the relative conversion in the outflow fell below 
95 % (Fig. 2). In order to check whether, with the residual biocatalyst activity present in the 
system, the conversion could be brought back to the desired level (i.e. 99%), the substrate 
feed rate was adjusted, according to the model estimates, to 1 x 10-9 m3 s-1 (see next 
section)  
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Figure 2 - Experimental data for relative conversions in the cascade during the first run  (ALR 1 - 
diamond, ALR 2 – square, ALR 3 – triangle) 
 
After a new steady state was reached (day 54), the residual substrate concentration in the 
outflow of the cascade fell to 1 % of the inflow value. In experimental run B a low catalyst 
load / high feed rate regime was applied. As predicted, only 64 % relative conversion was 
achieved under these conditions (data not shown). Continuous operation, conversions of 
99% and even higher (as achieved in run A), and facilitated recovery are all elements of 
competitive advantage for a biotransformation process. These facts, combined with the 
appropriate process optimization, could make a continuous deacylation with immobilized 
cells an interesting and economically viable alternative to the established batch process. 
 
Model estimates 
 
A model developed earlier in our laboratory14 was used to design the cascade of ALRs. The 
calculation procedure considers internal diffusion/reaction rate of the substrate in the 
immobilized biocatalyst beads suspended in ideally mixed reactors. By setting the desired 
degree of substrate conversion and starting with the last reactor in the cascade, the 
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dimensionless concentrations (i.e. conversion) were calculated for each reactor. 
Consequently, the holding times and, as a result, the volumes of reactors were calculated. 
Initial and operational values used in the model simulations are given in Materials and 
Methods section. The experimental conversions were determined daily and the biocatalyst 
decay rate (kd) was taken into account in the model calculations. The experimentally 
observed values and model output data are given in Table II. It clearly shows that 
calculated estimates agree well with the observed values in both experimental runs. When 
the conversion in the outflow fell to 95 % (day 42, Fig. 2) model calculations were used to 
adjust the flow rate so that the expected conversion is 99%. After steady state was reached 
with a new flow rate experimentally observed conversions indeed coincided with the 
predicted values (see previous section). This suggests that, considering the range of the 
experimentally examined conditions, the proposed model can be employed as a tool to 
design and also adequately interpret the deacylation of A40926.  
 
Table II – Experimental data and model calculated values for the first and the second run, obtained 
after 56 days of operation.  
Run A Run B 
Parameter 
Experimental Model Experimental Model 
Vtot [10-3 m3] a 1.29 1.31 1.29 1.30 
Crel 1 [%] b 63 62 28 30 
Crel 2 [%] b 87 90 50 52 
Crel 3 [%] b 99 99 64 67 
 
a total working volume of  three air-lift reactors 
b relative conversions (expressed as ratio of product concentration to inlet  substrate concentration) 
in each reactor of the cascade 
 
As mentioned before, the model considers heterogeneous biocatalysis where the diffusion 
and the conversion of the substrate in the immobilized biocatalyst bead simultaneously 
occur. Concomitant diffusion/reaction situations imply a progressive decrease of the 
substrate concentration in the beads. By implementing the concept of the Thiele modulus20 
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in the calculation procedure, the model can estimate the effectiveness factors and the 
substrate concentration in the bead. In Figure 3, a concentration profile for a biocatalyst 
bead in the last airlift reactor of the experimental run A is shown.  
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Figure 3 - Estimated substrate concentration profile in a biocatalyst bead present in the last air-lift 
reactor during the first experimental run (R/R0 –normalized bead radius; C/Cs – substrate 
concentration normalized to the substrate concentration on the surface of the bead) 
 
The calculated profile suggests that all of the biocatalyst present in the bead is in contact 
with the substrate. It is also evident that the substrate concentration in the centre of the bead 
is about 65 % of the substrate bulk concentration. In this case overall effectiveness factor 
was calculated to be 0.94 and considering that the Km value is quite lower than the substrate 
concentration in the centre of the bead, it is clear that A40926 diffusion in the bead is not 
limiting the biotransformation rate to a high extent. 
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Conclusions 
 
Using immobilized Actinoplanes teichomyceticus cells a continuous biotransformation of 
A40926 was investigated in a series of three airlift loop-reactors. To design the cascade and 
evaluate a range of experimental conditions, a model developed by of De Gooijer et al.14 
was used. Distinct operational regimes were examined in independent experimental trials. 
In both runs the cascade system was operated continuously for two months. The model 
estimates obtained for reactor volumes and substrate conversions agreed well with the 
experimental results. Under the operational regime of high biocatalyst gel load and low 
substrate feed rate, 95-99% conversions were achieved and maintained throughout the two 
months of operation. These results demonstrate the feasibility of the continuous 
biotransformation of A40926 at laboratory scale.  
 
If the new process is to be brought to industrial scale, the competitiveness of the continuous 
deacylation must be demonstrated. A very high final conversion combined with an 
extensive continuous operation time represents a strong competitive advantage of the 
continuous process over the established batch deacylation. These parameters might even be 
improved by increasing the biocatalyst gel load and/or the reactor gel hold-up (conditions 
still physically possible). Thus, there is a ground for the further improvement of the 
continuous process by suitable combination of operational parameters. For that purpose, the 
proposed model was demonstrated to be a powerful design tool and could be used for 
adequate scale-up and subsequent process optimization. 
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Factors influencing A40926 antibiotic complex production in Nonomuraea sp. 
Abstract 
 
A40926 is a glycopeptide antibiotic complex consisting of several structurally related 
factors. It is produced by fermentation of Nonomuraea sp. ATCC 39727 and the complex 
components differ in the structure of the fatty acid moiety linked to the aminoglucuronic 
acid unit. In previous work we observed that the production of single factors in 
glycopeptide antibiotic complexes, could be selectively enhanced by the addition of 
suitable precursors to the culture medium. In this contribution we examine the effects of 
branched amino acid addition to fermentation of Nonomuraea sp. in a chemically defined 
minimal medium. The changes in the composition of cell fatty acids correlate to the fatty 
acid distribution within the A40926 complex in diverse cultivation conditions. Nonomuraea 
sp. prefers isobutyric, butyric and propionic acids as initiators of fatty acid biosynthesis. 
The relative amount of the produced fatty acids is significantly influenced by the 
availability of intermediates or final products from the amino acid catabolic pathways. 
Antibiotic complex composition closely reflects the cell fatty acid pattern, in agreement 
with the assumption that the antibiotic fatty acid moieties are synthesized by shortening the 
chain of cell fatty acids. 
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Introduction 
 
Our interest in fatty acid metabolism in Nonomuraea ATTC 39727 derives from the 
observation of the close structural relationship between cell fatty acids and the shorter fatty 
acid moieties, which characterize the single components in the antibiotic complex produced 
by the strain. Nonomuraea cultures produce antibiotic A409266, which is the starting 
material for the synthesis of dalbavancin, a clinically effective antibacterial antibiotic 5. 
A40926 is a complex comprised of several structurally related factors (Fig 1). Complex 
components are known to differ in the structure of the fatty acid moiety (R1) linked to the 
glucuronic acid residue of the molecule 19,20. Main components of the complex are A0 (R1 = 
iso-C11:0), A1 (R1 = n-C11:0), B0 (R1 = iso-C12:0) and B1 (R1 = n-C12:0). 
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Figure 1 - A40926 chemical structure. Complex components differ in the acyl moieties substituted 
in the position R1 of the molecule. 
 
The origin of the fatty acids constituting the acyl moieties of the glycopeptide molecules 
has been previously studied in the structurally closely related teicoplanin 2, A4092620 and in 
the lipopeptide antibiotic ramoplanin3. Borghi et al.2 studied factors affecting the normal 
and branched-chain acyl moieties of teicoplanin, and demonstrated that teicoplanin acyl 
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moieties are biosynthesized from longer cell fatty acids by shortening of the carbon chains. 
Since apparently the shortening is performed by the classical β-oxidation mechanism by 
loss of acetic acid units starting from the carboxyl end, the characteristic end terminal 
features (branched or linear) are conserved. Moreover the characteristic even or odd 
number of carbons is also conserved. The hypothesis was confirmed by the biosynthesis of 
novel teicoplanins bearing ten carbon chains with structural variations by adding to the 
culture medium C18 acids having corresponding structural features 12.  
 
The biosynthesis of linear and branched fatty acids in prokaryotes has been elucidated in 
detail 10. Branched chain fatty acids are synthesized using as chain initiator the coenzyme A 
esters of isobutyric acid (resulting in fatty acid with an even number of C atoms), isovaleric 
acid  (resulting in fatty acid with an odd number of carbon atoms) or 2-methyl butyric acid 
(resulting in ante-iso fatty acid with an odd number of C atoms). These initiators can be 
easily provided by reactions, common to all branched amino acids catabolic pathways, 
consisting of the conversion by valine dehydrogenase of the amino acids into the 
corresponding α-ketoacids, namely α-ketoisovaleric, α-ketoisocapronic and 3-methyl-α-
ketovaleric acids followed by oxidative decarboxylation. However, other ways of 
synthesizing the primers are known: we may note that all the above α -ketoacids are 
produced as intermediates in the pathway of branched amino acid synthesis, and that in 
Streptomyces spp. isobutyric acid can by formed by isomerisation of n-butyric acid 8. The 
biosynthesis of branched chain and straight chain fatty acids in actinomycetes has been 
studied17,18 by adding predeuterated precursors to cultures grown on an amino acid rich 
medium. The nature and the origin of the chain initiators was demonstrated the same as that 
of bacilli. In the present contribution we examine the biosynthesis of fatty acids in 
Nonomuraea cultures grown in a chemically defined minimal medium containing 
ammonium ions as the only nitrogen source. In particular we assess the capacity of the 
strain of synthesizing the starters for the fatty acid chains, and the effect of biosynthetic 
precursors on both cell fatty acid composition and A40926 complex composition in the 
absence of potentially interfering nutrients usually present in rich media. 
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Materials and methods 
 
Strains and Cultural Conditions 
 
Nonomuraea sp. ATTC 39727 was maintained as a frozen vegetative stock at –80 °C in 15 
% glycerol at a biomass concentration of approximately 0.08 g/ml DW (dry weight). 
Fermentation in the chemically defined minimal medium P150 7 was carried out in shake-
flasks. For vegetative seed culture preparations, a 500 ml baffled Erlenmeyer flask 
containing 100 ml seed medium described by Beltrametti et al. 1 was inoculated with one 
glycerol stock vial and incubated for 96 h at 28 °C on a rotary shaker (200 rpm). 
Subsequently, seed culture was used for inoculating (at 10 % v/v) 100 ml aliquots of 
medium P150, and medium P150 supplemented with either 0.5 g/l of valine, 0.5 g/l of L-
leucine or with 0.5 g/l of L-isoleucine, in 500 ml baffled Erlenmeyer flask. The shake-
flasks were incubated at temperature of 28 °C on a rotary shaker (200 rpm) and 
fermentation monitored for 96 h. 
 
Analysis 
 
Fermentation broth samples were collected at regular time intervals and analysed. 
Antibiotic production was monitored by HPLC analysis, as described by Beltrametti et al. 1 
Biomass concentrations were determined by means of dry weight measurements. Glucose 
was analysed using Trinder assay (SIGMA Diagnostics, St. Louis, MO,USA). Inorganic 
phosphate was determined by malachite green method 4. The indophenol direct method was 
used to assay ammonium concentrations9. After 72 h of fermentation, composition of the 
cell fatty acids was determined as fatty acid methyl esters derivatives (FAMEs) by GC-MS 
method, previously described by Beltrametti et al.1 
96 
Factors influencing A40926 antibiotic complex production in Nonomuraea sp. 
Results and Discussion 
 
Growth and production in minimal medium  
 
The fermentation parameters of Nonomuraea sp. grown in the chemically defined P150 
medium without amino acid supplements (i.e. reference conditions) are given in Fig. 2.  
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Figure 2 - Fermentation time course of Nonomuraea sp. grown in chemically defined P150 medium 
(error bars give a 95 % confidence region). 
 
Data are mean values from three replicas of fermentations and each measurement was 
independently repeated three times. In contrast to what is commonly known for many 
secondary metabolites, the production of the A40926 antibiotic was found to be partly 
associated with the cell growth. This pattern was consistent with batch fermentation data 
previously reported by Gunnarson et al.7. Maximum antibiotic production of 16 mg/l was 
observed after 72 h of growth and it coincided with glucose exhaustion and concomitant 
end of biomass growth. At this culture time, samples of mycelium were collected and the 
composition of cell fatty acids was determined by GS-MS of their methyl esters (FAME). 
To study the effect of branched amino acids, the fermentation was repeated by adding to the 
medium 0.5 g/l of L-valine, L-leucine or L-isoleucine respectively and the composition of 
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the antibiotic complex as well as of the whole cell fatty acids was determined. Using 
relative abundance values, the percent contribution of the various FAMEs to the fatty acid 
composition was calculated and given in Table1. 
 
Table 1: Composition of cell fatty acids found under different fermentation and analysed as FAMEs 
in GC-MS. 
 
  area% 
Rt [min] Fatty acid P150 P150 + Val P150 + Leu P150 + Ile 
13,94 i 14:0 - 0,64 0,61 0,56 
14,96 n 14:0 4,44 2,76 2,78 1,82 
16,65 i 15:0 1,16 3,52 5,02 2,69 
17,61 n 15:0 1,68 6,54 1,35 10,33 
18,63 n 14:0 3-OH 0,65 2,40 3,41 2,36 
19,23 i 16:0 8,18 26,30 36,37 17,41 
19,58 16:1 ,9 6,30 0,80 0,46 0,44 
20,17 n 16:0 27,97 11,96 10,21 13,66 
20,5 n 15:0 3-OH - - 17,38 1,23 
21,25 n 16:0 10 met 13,16 1,87 3,33 1,28 
21,72 i 17:0 0,78 0,76 1,78 - 
21,96 n 17:1 ,9 1,21 3,36 0,99 4,59 
22,62 n 17:0 1,20 4,87 1,05 6,41 
23,59 n 17:0 10 met 8,40 23,98 8,02 32,21 
24,28 n 18:1 ,9 2,92 0,91 0,40 - 
24,73 n 17:0 3-OH - - - 1,52 
24,97 n 18:0 2,53 4,81 2,98 1,99 
25,86 n 18:0 10 met 16,96 1,72 3,23 1,24 
27,21 n 19:0 1,06 0,82 0,22 - 
29,39 n 20:0 1,39 1,97 0,40 0,25 
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Cell fatty acid composition in minimal medium 
 
In cells grown in medium P150 without supplements, linear acids with an even number of 
carbons predominated (Fig.3a and Table 1).  
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Figure 3 a&b - FAME GC-MS profiles for Nonomuraea sp. ATCC 39727 cell fatty acids from 
cultures grown in the chemically defined minimal medium P150 (a), and in medium 
P150 supplemented with 0.5 g/l of L-valine (b). Peaks relevant for the discussion are 
indicated. 
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The major component was n-C16:0. Summing up the contribution of the two linear 
hexadecanoic acids (n-C16:0 and n-C16:1), it overcame the 35% of the total. This suggests 
a large availability of butyrate, previously identified as the primer of such hexadecanoic 
acids either in bacilli or in actinomycetes17,18. Among the linear acids primed by propionate, 
10-methylheptadecanoic acid predominated (8,40%). This is not surprising since according 
to Kroppenstedt et al.11 and Zhang et al.21, the presence of this acid is a typical taxonomical 
feature of Nonomuraea genus. Acids, whose synthesis is initiated by isobutyrate (iso-
C16:0), contributed with the 8.18% to the total, and those initiated by isovalerate 
contributed with merely the 2.46%. Given the apparent large availability of butyrate, we 
can surmise that in our cells isobutyrate derived mainly from the butyrate isomerisation. 
Indeed, a pathway of butyrate synthesis from acetate and its conversion to isobutyrate was 
previously demonstrated in Streptomyces spp. by several studies (Han et al.8 and the 
literature therein quoted). In agreement with the fatty acid composition typical for 
Nonomuraea genus, anteiso- acids were not detected (Fig.3a and Table 1). This fatty acid 
composition of Nonomuraea cells grown in minimal medium, substantially differs from 
that reported by Zerilli et al. 20 for Nonomuraea cells grown in a complex medium. In that 
condition, the two predominant components were iso-hexadecanoic acid and 10-
methyleptadecanoic acid. The first is primed by isobutyric acid, obviously provided by the 
partial catabolism of L-valine present in the culture medium. The second is primed by 
propionate, which is the end product of the catabolism of L-leucine and L-valine in many 
organisms 13 including streptomycetes 14, 16. 
 
L-Valine effect on cell fatty acid composition  
 
In a previous paper from our laboratory, Beltrametti et al. 1 compared the pattern of fatty 
acid of cells grown in P150 medium with that of cells grown in P150 medium plus 0.75 g/l 
of L-valine. Beside a positive effect on antibiotic titre (see below), L-valine addition 
resulted in a substantial increase of iso-C16:0 acid coupled with a significant decrease in 
the relative amount of linear n-C16:0 acid. The results hereby presented (Fig.3b and Table 
1) obtained with 0.5 g/l of L-valine, revealed that iso-C16:0 was in fact predominant, 
representing the 26.30 % of the total, whereas n-C16:0 contribution was decreased from 
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about 30% to about 12%. Another major effect of L-valine appeared to be the increase of n-
C17:0-10-methyl acid from 8,40% to 23,98%. The biosynthesis of this chain is initiated by 
propionate, which is the end product of L-valine catabolism pathway. Other relevant 
amounts were those of n-C17:0 and n-C15:0 acids (4,87% and 6,54% respectively) also 
primed by propionate.  
 
L-Leucine effect on cell fatty acid composition 
 
When P150 medium was supplemented with 0.5 g/l of L-leucine or L-isoleucine, no 
significant changes in the fermentation trend or in the total antibiotic production were 
observed (data not shown). However upon addition of 0.5 g/l of L-leucine, important 
changes in cell fatty acid composition could be noticed (Fig.3c and Table 1). The 
contribution of iso-fatty acids with an odd number of carbon (iso-C15:0 and iso-C17:0) 
increased to 6.80% from the 1,84% observed in the un-supplemented medium. This was 
indeed a relatively small contribution, indicating that isovalerate is a poor substrate for the 
fatty acid synthase and therefore is largely available to be converted into isobutyric acid, 
the end product of L-leucine catabolic pathway. This is consistent with the unpredicted 
large increase of iso-C16:0, which represented the 36,37% of the total. It may be added that 
a secondary way of formation of isobutyric acid is possible. In fact, in many bacteria, L-
leucine in relatively low concentrations inhibits the activity of α-isopropylmalate synthase, 
which catalyses the first step of leucine synthetic pathway, i.e. the conversion of α-
ketoisovalerate into α-isopropylmalate. As a consequence, α-ketoisovalerate may 
accumulate and give rise, through oxidative decarboxylation, to isobutyric acid. 
Considering the other relevant acid it can be observed that the sum of the amounts of linear 
acids primed by propionate (n-C15:0, n-C17:0, n-C17:1, n-C17:0 10 Met), is approximately 
one third of the amount of iso-C16:0. 
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Figure 3 c&d - FAME GC-MS profiles for Nonomuraea sp. ATCC 39727 cell fatty acids from 
cultures grown in the chemically defined medium P150 supplemented with 0.5 g/l of 
L-leucine (c) or L-isoleucine (d). Peaks relevant for the discussion are indicated. 
 
L-isoleucine effect on cell fatty acid composition 
 
Addition of L-isoleucine to the fermentation medium resulted in a striking increase of odd-
carbon linear fatty acids, namely n-C15:0 (11,14%), n-17:0 (6,91%), n-17:1 (4,95%) and n-
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C17:0-10 met (34,35%) (Fig.3d and Table 1). This was understandable considering that 
propionyl-CoA and acetyl-CoA are the end products from L-leucine catabolic pathway. The 
first could be directly used for odd-carbon acid initiation. Acetyl-CoA, according to the 
above-mentioned pathway, could produce butyrate or isobutyrate and contribute to the 
synthesis of the observed iso-C16:0 and n-C16:0. No anteiso- fatty acids were observed, in 
spite of the demonstrated role of L-isoleucine as enhancer of their synthesis in many 
organisms. This suggests that the 2-methylbutyrate produced by L-isoleucine degradation is 
not recognized as a suitable substrate for fatty acid initiation in Nonomuraea sp. 
 
A40926 complex composition  
As mentioned before, the acyl moieties in the A40926 complex are believed to originate 
from the degradation of cell fatty acids. Analysis of the A40926 complex produced in the 
described conditions, confirmed this assumption. The relative abundance of A40926 main 
factors is given in Fig.4. In the fermentations carried out in medium P150 without 
supplements, the major antibiotic component was factor B1, characterized by n-C12:0 acyl 
moiety. Its amount is 2.8 folds that of component B0 (iso-C12:0) and is 12.2 and 20 folds 
that of components A1 (n-C11:0) and A0 (iso-C11:0), respectively. There is a qualitatively 
good correspondence between A40926 complex and the cell fatty acid pattern, considering 
that the linear hexadecanoic acis predominated among fatty acids, followed in the order by 
the iso-hexadeanoic, the heptadecanoic acids and then by the acids primed by isovalerate. 
Following the addition of L-valine (Fig.4), the change in fatty acid composition was 
reflected by the change in the antibiotic complex composition. Component B0, 
characterized by an iso-C12:0 chain, became the major component of the antibiotic 
complex, in agreement with iso-C16:0 being the major component among cell fatty acids. 
The remarkable increase in n–C15:0 and n-C17:0 fatty acids was reflected by a major 
increase of A40926 factor A1 (n-C11:0) synthesis. However, it appears evident that the 10-
methyl-heptadecanoic acid, about as abundant as the iso-C16:0 acid, did not contribute to 
the formation of the n-C11:0 moiety of factor A1. In fact, by the loss of three acetate units, 
the acid would be converted into the 4-methyl-undecanoic acid, not accepted as a substrate 
by the transacylase. 
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Figure 4 - Composition of the A40926 complex in the chemically defined minimal medium P150 
and in medium P150 supplemented with 0.5 g/l of L-valine or L-leucine or L-isoleucine 
(error bars give a 95 % confidence region). The structures of the chains characterizing the 
factors are indicated. 
 
The small amount of factor A0 is consistent with the minor contribution of iso-C15:0 to the 
cell fatty acids. In the case of L-leucine addition (Fig.4), as could be predicted from the 
fatty acid composition, factor B0 was the major constituent of the antibiotic complex. In 
spite of a five times increase with respect to reference condition, the contribution of factor 
A0 (characterized by an iso-C11:0 chain) was still inferior to that of factor B1 (with a n-
C12:0 chain), consistently with the ratios of the fatty acids from which they respectively 
derive. When L-isoleucine was added (Fig.4), 10-methyl-hexadecanoic was the 
predominant cell fatty acid. As discussed above, this acid could not contribute to the 
formation of the antibiotic fatty acid moieties. All together the other acids initiated by 
propionate represented the 23% of the total, versus the 17.91% of those initiated by 
butyrate and the 17,41% of those initiated by isobutyrate. This distribution was reflected in 
the composition of the antibiotic complex in which factor A1 predominated, followed in the 
order by factors B1 and B0. 
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In conclusion, when a single branched amino acid was added to the fermentation medium, 
the biosynthesis of fatty acids was influenced not only by the products of the initial steps of 
its catabolism, but also by the end products of the pathway, which, as it is the case of 
propionate, acted as the starters of specific fatty acids. The overall result depended on a 
combination of the biosynthetic starters‘ availability with the affinity of the starters for the 
synthase. It is evident that in Nonomuraea cells, three units, namely butyryl-CoA, 
isobutyryl-CoA and propionyl-CoA were about equally efficient in promoting the 
biosynthesis. Isovaleryl-CoA was accepted as a substrate to a lesser extent and 2-
methylbutyryl-CoA was not recognized as a promoter. As a consequence in the case of L-
isoleucine addition, no anteiso fatty acids were synthesized and the complete catabolism of 
the amino acid provided large amounts of propionyl-CoA, the primer of fatty acids with an 
even number of carbons. The case of L-leucine is also interesting since, due to the low 
affinity of isovalerate for the synthase, this intermediate was largely available for further 
degradation and was metabolized into isobutiryl-CoA, the end product of L-leucine 
catabolism. Therefore the prominent cell fatty acid was the iso-hexadecanoate, rather than 
the expected iso-C15 or iso-C17 acids. 
 
In all the conditions examined, either in the absence or in presence of different amino acids, 
the relative proportion of the components in the antibiotic complex was qualitatively 
corresponding to the distribution of cell fatty acids. This could hardly be the case if the 
antibiotic acidic moieties were synthesized ex novo by a different synthase, and therefore 
constitutes a further confirmation of the origin of these moieties as degradation products 
from longer chain fatty acids. Sequencing of A40926 biosynthetic gene cluster 15 revealed 
that genes devoted to fatty acid synthesis were not present in the indeed complete and 
highly organized cluster, further indicating that the acyl moieties introduced in the A40926 
originate from cell fatty acid turnover. This observation may be of practical value since it 
indicates the possibility of altering the composition of the A40926 complex by the addition 
of suitable precursors and of obtaining new derivatives by supplementing the fermentation 
medium with sixteen- or eighteen-carbons acids bearing desired structural features.  
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General Discussion 
Introduction 
 
This thesis focuses on the biotransformation of glycopeptide A40926 by immobilized cells 
of Actynoplanes teichomyceticus to produce a deacylated derivative. Deacyl-A40926 is 
used as a basic scaffold for medicinal chemistry modifications aiming to expand and 
improve the spectrum and/or potency of semisynthetic second-generation glycopeptide 
antibiotics. These antibiotics are today (still) considered as last line of defence against one 
of the most important human health threats, Multi-Resistant Staphylococcus aureus. 
A40926 is a natural antibiotic found in the fermentation broths of Nonomuraea sp. (a rare 
Actynomcete isolated from soil) and it demonstrates strong inhibitory activity against 
Gram-positive bacteria and Neisseria gonorrhoea. Like many other natural antibiotics, 
A40926 is a secondary metabolite of a quite complex structure. It is a mixture of several 
structurally very closely related compounds (called factors) that only differ in the type of 
the substituent present in the acyl-chain moiety of the molecule (Fig. 1). The origin and 
some aspects of these structural differences are adressed in Chapter 6, suggesting that novel 
derivatives might also be obtained by directed biosynthesis.  
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Figure 1 - A40926 chemical structure. Components of A40926 (factors A0 , A1, B0 and 
B1) differ in the acyl chain substituent in the position R1 of the molecule. 
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The multifaceted structure makes A40926 a challenging scaffold for derivatization. This 
combined with an excellent activity against Gram-positive Staphylococcus aureus  offer  a 
unique opportunity for the discovery and the development of new semisynthetic 
glycopeptide antibiotics. However, chemical modification, such as deacylation, of a 
complex glycopeptide molecule is an almost impossible task and the solutions are often 
sought in the form of biotransformation. We employed A. teichomyceticus cells for 
biocatalytic deacylation of A40926 (selective cleaving a fatty acid side chain of the 
molecule (R1 in Fig.1 )) to obtain the desired deacyl-A40926 derivative (Chapter 2). This 
biotransformation is carried out with whole resting cells. Because we were developing a 
continuous process with non-growing cells, catalyst retention in the reactor was required. 
This is achieved by immobilizing cells in a Ca-alginate gel as a solid support (Chapter 2). 
Immobilized whole cell biocatalysis is most efficient when it is used in a continuous 
fashion, maximizing utilization of the catalyst. In a single lab-scale air-lift reactor 
continuous deacylation was accomplished (Chapter 4). We demonstrated that the process 
could stably operate for 3 weeks with an overall conversion of  about 60%. Nonetheless, 
two important constraints necessitated overall bioconversion to be greater than 99%: 1) the 
very high costs of the substrate (A40926 itself is a natural antibiotic isolated from the 
fermentation broths through a complex recovery process), and 2) the very high purity of the 
final product needed (deacyl-A40926 is subsequently used for selective reacylation to 
generate novel derivatives).  The solution to this was finally found in a series of three 
perfectly mixed air-lift bioreactors (Chapter 5). A continuously operated cascade system 
was run for almost two months with an overall  conversion of >99%, demonstrating the 
feasibility of the continuous deacylation at the lab-scale. With this process configuration we 
were able to produce gram quantities of deacyl-A40926.  
 
As discussed above, deacyl-A40926 is an ideal scaffold that can be selectively reacylated 
with differrent acyl chains or functional groups to generate novel and more potent 
compounds. It is also an indispensable element for structure-activity relationships (SAR) 
studies, an essential part of a continuous search for better glycopeptides. Further on in this 
chapter we discuss this never ending battle against multi-resistant bacteria togheter with 
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some recent developments and possible alternatives in quest of better drugs and /or 
treatments against MRSA.  
 
It all begun with penicillins 
The use of penicillin as an antibiotic is one of the most important breakthroughs in human 
health care. Although penicillin was discovered by Fleming in 1928, its application was not 
realized until Chain and Florey contributed their efforts about a decade later1. Fleming, 
Chain and Florey won the Nobel Prize in 1945 for the discovery of penicillin and its 
curative effect in infectious diseases 2. Since then, penicillin and many of its derivatives 
have become, and still are, the first-line medicine to treat bacterial infections. The 
development of large-scale production processes for penicillins has strongly stimulated the 
development of modern biotechnology. Most antibiotics prescribed today are derivatives of 
the ‘natural’ antibiotics produced by micro-organisms. A prominent example is the broad-
spectrum semi-synthetic antibiotic and blockbuster amoxicillin that is derived from 
penicillin. Although most antibiotics used today were first employed 25 years or so ago, 
their manufacturing processes are still subject to significant improvement (Box 1). An 
elegant example is the protein evolution of a glutaryl acylase to produce a catalyst for the 
single-step (instead of two-step) hydrolysis of cephalosporin C into 7-aminocephalosporic 
acid (7-ACA)3. 
 
Box 1. The Chemferm-project. 
 
In 2001 a large research project on the synthesis of ß-lactam antibiotics (penicillins and 
cephalosporins) was ended and the results summarized in a book4. It started as collaboration between 
three Dutch companies, DSM, Gist-brocades and their joint-venture Chemferm, and six academic 
groups at four Dutch universities. During the project the number of companies involved was reduced 
to one by the merger of DSM and Gist-brocades. The project was co-financed by the Dutch Ministry 
of Economic Affairs. A multi-disciplinary team of experts studied the scope and limitations of 
biocatalytic routes to the industrially most relevant penicillins and cephalosporins, as schematized in 
the general production chart in Figure 2. The results of the five-year intensive cooperation were 
published in over 100 scientific papers and several patents, representing guidelines for the 
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technological future of DSM Anti Infectives within the context of its business development. 
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Figure 2 - General production chart of penicillin-derived antibiotics (semi-synthetic penicillins, 
SSP’s, e.g. ampicillin (R = H) and amoxicillin (R = OH)) and cephalosporin-derived 
antibiotics (SSC’s, e.g. cephalexin (R = H) and cephadroxil (R = OH)). Intermediates: 6-
aminopenicillanic acid (6-APA) and 7-aminodesacetoxy-cephalosporanic acid (7-
ADCA). Reproduced with permission from Tramper et al.5. 
 
The occurrence of resistance 
Only four years after pharmaceutical companies started manufacturing penicillin, bacteria 
began appearing that were resistant to it. Staphylococcus aureus, a Gram-positive 
bacterium that causes severe illnesses such as pneumonia and surgical-wound infections, 
could destroy penicillin by expressing the enzyme β-lactamase. In the late 1950’s, 
penicillin was effective against only 15% of Staphylococcus aureus infections. The 
pharmaceutical industry responded to this emergence with methicillin, a β-lactamase-
insensitive semi-synthetic penicillin. However, the first resistant clinical bacterial isolates 
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appeared in Europe during the 1960s, only a few years after the clinical introduction of 
methicillin. The crucial spread, however, started in the early 1980s in American hospitals. 
The resistant strain obtained the name methicillin-resistant Staphylococcus aureus, and 
later multi-resistant Staphylococcus aureus (MRSA), due to its resistance to against all β-
lactam antibiotics. 
 
Because bacterial evolution towards antibiotic resistance is considered  a constant process 
the major effort of the health authorities and institutions is on delaying dissemination of 
resistant bacteria and/or resistance genes6. Resistance can result from mutations in resident 
structural or regulatory genes or from horizontal acquisition of foreign genetic information. 
Major resistance mechanisms can be distinguished: 
1. Modification of the target that leads to loss or decreased affinity of the drug for its 
target, as for the mutated β-lactam-resistant transpeptidase. 
2. Production of an enzyme that will detoxify the drug, such as β-lactamase. 
3. Impermeability, in particular by reducing the number or the diameter of a porin 
(pore in the external membrane) in Gram-negative bacteria. 
4. Efflux of antibiotics to the exterior of the bacterial cells by energy-dependent 
pumps, either in Gram-positive or Gram-negative pathogens. 
The common objective of these various mechanisms is to impede interaction of the 
antibiotic with its target. 
 
Antibiotics are classified according to their chemical structure, allowing division into four 
main classes: ß-lactams, aminoglycosides, glycopeptides and macrolides. Members within a 
same class have similar molecular structures and generally the same antibiotic spectrum. 
They are, therefore, subject to cross-resistance by the two major ways that bacteria have 
developed: 
1. By target alteration (mechanism 1 mentioned above), because the members share 
the same spectrum. 
2. By making the members innocuous (mechanisms 2, 3 and 4 mentioned above), 
because they are structurally similar. 
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Thus, the resistance should be considered in terms of drug classes rather than in terms of 
isolated molecules6.  
 
Alternatively to β-lactams, other antibacterials have been used against MRSA infections, 
e.g. tetracyclines, erythromycin, aminoglycosides and more recently the chemically derived 
fluoroquinolones. However, as a result of transposition and site-specific integrations of 
genetic information under the selective pressure exerted by the massive use and misuse of 
antibiotics, many MRSAs have acquired resistance genes thus becoming insensitive to 
almost all known antibiotic classes. This situation where bacterial pathogens are evolving 
to become resistant to the full range of clinically useful antibiotics is a threatening scenario, 
almost equivalent to a return to the pre-antibiotic era. 7 At present, the centre of concern is 
the antibiotic vancomycin that, for many infections, is literally the drug of ‘last resort’. 
Some hospital-acquired Staphylococcus aureus infections are now resistant to all antibiotics 
except vancomycin8. 
 
Unfortunately, vancomycin resistance has arisen in other common hospital bugs, i.e. 
enterococci, which are normally found in the human gut. The speed with which 
vancomycin resistance spread through enterococci prompted researchers to use the word 
‘crisis’ when discussing the possibility of a vancomycin-resistant Staphylococcus aureus 
(VRSA)9. Indeed in 1997, signs of vancomycin intermediate-resistant Staphylococcus 
aureus (VISA) were noted in patients hospitalized in three geographically different 
locations. Only a few years later, highly resistant VRSAs were isolated following an event 
of in vivo horizontal resistant-gene transfer from Enterococcus faecalis to MRSA clinical 
isolates10. This alarm was taken seriously by all health authorities because vancomycin was 
thought the only weapon available against this strain. Clearly, resistance was indeed 
encroaching what is considered the last bastion of clinically effective antimicrobial agents, 
i.e. vancomycin and its relatives, the glycopeptide antibiotics11. For a long time scientists 
and clinicians optimistically predicted that glycopeptide resistance would never occur 
because glycopeptides inhibit late steps in bacterial cell wall peptidoglycan synthesis, an 
antibiotic target difficult to modify for bacteria. However, as one of the most remarkable 
118 
General Discussion 
resistance strategies, it has become apparent that bacteria can actually use multiple proteins 
encoded on mobile transposons to essentially re-engineer their peptidoglycan and prevent 
binding of the antibiotic vancomycin, while still retaining the structural integrity of their 
cell wall7. 
 
Glycopeptide antibiotics 
In 1956, scientists from Eli Lilly discovered vancomycin. They recovered this compound 
from the culture of the actinomycete Streptomyces orientalis, today classified as 
Amycolatopsis orientalis. The purified natural product exhibited lethal properties against all 
tested strains of Staphylococcus and other Gram-positive bacteria. The substance was 
coined vancomycin, the name being derived from the verb ‘to vanquish’. Vancomycin 
became available for clinical use upon its FDA approval in 1958. The introduction of 
vancomycin as an anti-staphylococcal agent was followed shortly thereafter by methicillin 
and cephalosporins, drugs that initially received wider clinical acceptance in contrast to 
vancomycin because of the apparent toxic side effects of the latter. Vancomycin popularity 
increased as its purity improved, which alleviated many side effects. Today, vancomycin 
and its sister antibiotic teicoplanin, the latter being discovered by researchers of the Lepetit 
group (Box 2) and introduced in clinics in Europe in 198812, are still indispensable weapons 
of the clinician facing life-threatening situations with patients infected with Gram-positive, 
drug-resistant bacterial strains. 
 
Box 2. Vicissitudes of a typical anti-infectives biotech company. 
 
Lepetit Research Centre was until 1995 a medium-sized (100-150 employees) research laboratory, 
belonging to Marion Merrell Dow, devoted to the discovery and development of novel anti-infectives. 
It was established in Gerenzano near Milan, Italy. Lepetit discovered rifamycin followed by 
teicoplanin, ramoplanin, lantibiotic actagardine, A40926 and dalbavancin. In 1995 Lepetit was 
bought by Hoechst and turned into Hoechst Marion Roussel, representing the pharmaceutical branch 
of Hoechst. As result of this operation Biosearch Italia arose as a spin-off in 1997. Biosearch Italia 
presented itself as a small Italian biopharmaceutical company focusing on new antibiotics for the 
treatment of infections caused by multi-resistant bacteria. They specialized in glycopeptides, the class 
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of antibiotics to which vancomycin, teicoplanin, A40926 and dalbavancin belong. At that time the 
company worked together with Wageningen University, the Netherlands, on the de-acylation of 
A40926 (Figure 3) with immobilized cells in airlift bioreactors. In 2000 Biosearch Italia became the 
first small biotech company in Italy that went public and appeared on the Nuovo Mercato stock 
exchange. Then in 2003 it merged with the American biopharmaceutical company Fremont-based 
Versicor Inc. into Vicuron Pharmaceuticals (listed on both the NASDAQ and Nuovo Mercato stock 
exchange). At that time the company had three molecules in the clinical pipeline (Phase II and III), 
i.e. dalbavancin, anidulafungin and ramoplanin. In 2005 the company was bought by Pfizer for $ 1,9 
billion who brought anidulafungin on the market under the trade name Eraxis. In 2006 Pfizer decided 
to restructure its R&D and closed the research centre in Gerenzano. Since 2007 three of the former 
scientists go on as Actygea S.r.l., a starting biotech enterprise that focuses on R&D in the field of 
microbial products. 
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Figure 3. Biotransformation of A40926 t-BOC derivative to deacyl-A40926 t-BOC 
derivative by Actinoplanes teichomyceticus13. 
 
Before 1984, the glycopeptide class included few members beyond vancomycin and 
teicoplanin. With the threat of resistance, the class has rapidly grown since then. Hundreds 
of related natural products have been discovered meanwhile and thousands of semi-
synthetic analogues have been prepared. These constitute the class of compounds having a 
core heptapeptide scaffold containing aromatic amino acids that have undergone extensive 
oxidative cross-linking and decoration with different substituents such as sugar residues, 
chlorine atoms and/or lipid chains. Structural studies on these compounds have clarified the 
biological mode of action and serve as a basis for reasonable predictions regarding 
120 
General Discussion 
structure–activity relationships (SARs). Early attempts to elucidate the structure of 
vancomycin were hampered by impurities, lack of crystallinity, and structural complexity. 
With improvements in purification methods and development of newer spectroscopic 
techniques, pioneering studies on the structure of vancomycin became possible and, in 
1982, the complete structure was elucidated. Several other glycopeptides followed. In 1995, 
the first crystallographic analysis of an intact, naturally occurring glycopeptide antibiotic, 
balhimycin, was reported, and one year later the crystal structure of vancomycin was also 
established.  
 
As their name suggests, the glycopeptide antibiotics normally contain sugar moieties. A 
wide variety of carbohydrates have been found to occupy positions on the peptide 
backbone. These carbohydrate units are attached to the aglycon (the basic structure without 
sugar residues) through glycosidic bonds to phenolic or secondary hydroxy groups. The 
sugar groups of the glycopeptides play important roles in delivering the antibiotic to its 
target by modulating its solubility. The sugar domains of these molecules often promote a 
stronger binding and improved in vivo activity. The glycopeptide antibiotics exhibit various 
degrees of glycosidation, ranging from displaying no sugar residues, e.g. the vancomycin 
and teicoplanin aglycon, to carrying several sugar units with up to four glycosidic bonds 
linking them to the heptapeptide core, i.e. the highly adorned galacardin A (two 
disaccharides and two monosaccharides directly linked to the heptapeptide core. Box 3 
describes the mode of action of glycopeptides. 
 
Box 3 Mode of action of glycopeptides 
 
Glycopeptides are active against Gram-positive pathogens. They act by inhibiting the extracellular 
assembly of cell wall peptidoglycan. Binding of vancomycin to the bacterial cell wall was known long 
before its structural elucidation. Today, a precise structural picture for this interaction has been 
uncovered by NMR and X-ray crystallographic techniques. It is now known that vancomycin binds 
reversibly to the D-Ala-D-Ala fragment of a peptidoglycan precursor. This reversible, non-covalent 
interaction by five well-defined hydrogen bonds inhibits transglycosylation and transpeptidation from 
occurring (Figure 4). Inhibition of these processes leads to the collapse of the peptidoglycan by 
121 
Chapter 7 
decisively shifting its dynamic equilibrium towards de-assembly, which causes cell lysis and bacterial 
death. Further to this, a number of secondary effects of glycopeptide antibiotics enhance their 
potency. Prominent among these secondary effects are the abilities of a number of glycopeptides to 
dimerize in solution and of others to anchor themselves into the phospholipid bilayer by using 
lipophilic tails. NMR studies and X-ray crystallographic data show that vancomycin and a number of 
other glycopeptides could dimerize in solution to form ‘head-to-tail’ complexes. The dimeric 
structures, held together by four hydrogen bonds, contain two binding sites for L-Lys-D-Ala-D-Ala 
units. The tendency of glycopeptide antibiotics to dimerize has been correlated with their potency. 
Two hypothesis are currently used to explain this phenomenon. The first predicts a higher activity for 
a dimer because once half of the dimer binds to the substrate as usual, the other half then finds its 
target through what now becomes essentially intra-molecular binding.  
 
Figure 4 - Mechanisms of action of glycopeptides antibiotics (adapted from Nicolaou et al.11). 
 
This cooperative effect decreases the entropy factor for binding. The second hypothesis predicts 
increased activity through allosteric effects. Thus, the hydrogen bonding within the dimer enhances 
the ability of the binding pocket to bind the ligand by polarizing the amide bonds. This effect works in 
reverse as well. That is to say, the binding of the ligand also enhances the ability of the glycopeptide 
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antibiotic to dimerize. In contrast to vancomycin, teicoplanin exhibits high antibiotic activity despite 
its inability to dimerize in solution. An explanation for the enhanced potency of teicoplanin is 
provided by another secondary effect exhibited by a number of glycopeptide antibiotics, that of 
anchoring into the cell’s phospholipid bilayer through a long hydrocarbon chain. Thus, the lipophilic 
tail attached to one of its carbohydrate units of teicoplanin localizes the antibiotic to its site of action. 
To expand the antibiotic spectrum to Gram-negative bacteria chemists at the former Lepetit 
Laboratories (Box 2) prepared mideplanin by 3-(N,N-dimethylamino) propylamidation of teicoplanin. 
This derivative, and the one similarly derived from the teicoplanin aglycon, have some activity 
against both staphylococci and Gram-negative bacteria. Furthermore, two teicoplanin aglycon-
derived poly-(aminopropyl)amides also exhibited significant antibiotic activity against Gram-
negative bacteria. These modified glycopeptides do not differ from their parent compounds except for 
their ability to traverse the outer cell membrane of the Gram-negative bacteria by a self-promoted 
uptake mechanism14. 
 
Resistance build-up 
After several decades of use, appearance of the resistance to glycopeptides in enterococci, 
followed by its transfer to methicillin-resistant Staphylococcus aureus, came rather as a 
surprise 6. Drastic alterations in the synthesis of the peptidoglycan must have occurred to 
prevent binding with the antibiotic, and such changes would involve multiple mutations. 
Alteration of the target of glycopeptides by replacing the D-Ala-D-Ala terminus of the 
peptidoglycan precursor with the depsipeptide D-Ala-D-Lac reduces the antibiotic affinity 
by three orders of magnitude. This was not the result of spontaneous mutations in the 
clinical isolate, but it came from events of horizontal gene transfers from the glycopeptide-
producing microorganisms, where the set of van genes (so called since they confer 
vancomycin resistance) are useful to avoid self-inhibition during antibiotic production. Not 
only have enterococci acquired these genes that allow remodeling of the synthesis of the 
bacterial cell wall, but they did so in respecting the principle of parsimony. Acquired 
resistance to glycopeptides provides an interesting example of obligatory cooperation of 
resistance mechanisms, namely synthesis of a new ‘insensitive’ target (D-Ala-D-Lac) 
combined with removal of the previous ‘susceptible’ target (D-Ala-D-Ala). In fact the 
cluster of van genes comprises enzymes able to produce the D-Ala-D-Lac depsipeptide, but 
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also enzymes to remove the preformed D-Ala-D-Ala. As long as bacteria synthesize wild-
type precursors (D-Ala-D-Ala), they remain susceptible to the drugs. There is therefore a 
need to eliminate the normal precursors as the removal of the susceptible target lead to 
dominance of resistance versus susceptibility. This sophisticated resistance mechanism is 
presumably energetically extremely costly for the cell, which builds and then destroys cell 
wall precursors. Therefore activation of the resistance pathway and simultaneous 
deactivation of the chromosomal pathway should only occur when this switch in metabolic 
pathways confers a selective advantage to the host. It is therefore logical that the presence 
of sub-inhibitory concentrations of glycopeptides in the culture medium triggers expression 
of resistance. Although glycopeptide resistance was predicted not to occur, it could have 
been anticipated by the study of the producing microorganisms 6. Indeed, van genes 
encoding homologues of the resistance proteins in enterococci have been identified in the 
strains of Amycolatopsis orientalis, Actinoplanes teichomyceticus and Streptomyces 
toyocaensis that are used for the industrial production of vancomycin, teicoplanin and the 
sulfated teicoplanin-like aglycone A47934, respectively15, 16. 
 
Perspectives 
As we enter the 21st century we are faced with an ever-increasing need for a new generation 
of antibiotics capable of fighting the deadly, drug-resistant bacteria28.The urgency is 
aggravated even more, because of an almost empty clinical pipeline of new antibiotics. A 
remarkable innovation gap of almost 40 years that was witnessed, between the introduction 
of quinolones in 1962 and the approval of the next new structural class of antibiotic, the 
oxazolidinone linezolid (Zyvox), is a warning sign for the future. Inspecting the 
antibacterial drug candidates that are being advanced through clinical trials, it can be seen 
that the innovation gap still exists as many drug candidates under development continue to 
be minor modifications of the existing scaffolds. Another alarming indicator of the almost 
empty antibiotic clinical pipeline is the fact that few large pharmaceutical companies 
remain active in antibiotic development. The exit and/or de-emphasis of many 
pharmaceutical firms from this therapeutic area reflect not only a mix of economic and 
market projections, but also a partial to complete failure of research programs that have 
124 
General Discussion 
been built on existing models to find new leads that are robust enough to become clinical 
candidates 17. As a consequence, we witnessed in the last decade a shift in emphasis of anti-
bacterial R&D efforts away from many large pharmaceutical firms to a large contingent of 
biotech companies. This shift, combined with the entrepreneur approach to discovery, has 
led to a new wave of creativity in strategies, selection of targets, genomics, and 
development paradigms, but with scarce sucess.18. Following the publication in 1995 of the 
first whole-genome sequences of two bacterial pathogens – Haemophilus influenzae and 
Mycoplasma genitalium – both academic and industrial laboratories launched a wave of 
‘genomics’ efforts towards the identification of novel bacterial targets. The effort was 
typically an outstanding scientific accomplishment – usually paired with a DNA-sequence-
based genomic patent position on certain unique or proprietary targets – but no quality drug 
candidate emerged from these efforts 19. Striking example is a GlaxoSmithKline (GSK) 
campaign (1995-2001) to discover broad-spectrum antibiotics by the genomic approach. 
With the tools to search entire genomes for new antibacterial targets at hand, GSK 
evaluated more than 300 genes in 70 high-throughput campaigns over 7 years, but 
ultimately failed because of the limited chemical diversity of the synthetic screening 
libraries 22. It is therefore safe to say that a good established target is better than a new 
target. Thus, a novel strategies should consist of expanding the structural diversity and 
screening new compounds against well-established targets. This, in part, has already been 
happening in recent years through resurgence of the discovery of natural product antibiotics 
from bacterial sources.  As technology advanced, efforts have refocused either on finding 
new antibiotics from old sources (like streptomycetes) or from new sources (like other 
actinomycetes, cyanobacteria and uncultured bacteria)20, or on rediscovering old ones by 
semi-synthetic tailoring of natural product scaffolds. Focusing on those antibacterials that 
act by inhibiting cell wall biosynthesis, which still remains a well-established and robust 
target for natural product screenings, new or newly rediscovered antibiotics like 
oritavancin, telavancin and dalbavancin (a semi-synthetic derivative of A40926) where 
brought to a clinical development27. Very good examples of newly rediscovered 
compounds are mannopeptimycins, ramoplanin and lantibiotics. All of them inhibit some 
steps of the Lipid II cycle or block the flux of peptidoglycan precursors to the cross-linking 
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transglycosidases and transpeptidases (as outlined in Box 4).  
 
Box 4 The mannopeptimycins 
 
The mannopeptimycins are a family of glycopeptides first isolated from Streptomyces species in the 
1950s. They inhibit Lipid II-dependent peptidoglycan maturation by binding to Lipid II in a way that 
is different from other known compounds (Figure 5).  
 
 
 
 
Figure 5 - Lipid II pathway and site of action of mannopeptimycins and other lipid II inhibiting 
agents (adapted from Koehn21). 
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When mannopeptimycins were first discovered, they showed potent activity against Gram-positive 
organisms, but the chemical complexity of these compounds coupled with the lack of broad-spectrum 
activity reduced the prospects to further develop these antibiotics. The evolving clinical picture of 
bacterial resistance has today altered the profile of what are desirable antibiotics and creates 
opportunities for new strategies to discover them. Advances in HPLC, NMR, and mass spectrometry 
make it possible to isolate and structurally characterize what were previously intractable molecules. 
A semi-synthetic analogue program that sought to improve potency and in vivo activity resulted in a 
solid SAR picture and furnished numerous mannopeptimycin analogs with increased potency and 
serum stability21. 
 
While antibiotics are still our last line of the defense, it is evident that there is the critical 
need for novel effective therapies against bacterial infectious diseases. Such alternative 
therapies should ideally put no selective pressure toward insurgence of the resistance 
among the bacteria. Interesting advancements in this direction could be found in recent 
developments of combination drugs (Box 5), or phage therapies26, strategies that might 
become our additional weapons against multi-resistant bacteria 23, 24. Another emerging and 
very exciting resource for the discovery of new therapeutics are marine bacteria. They are 
considered to be a source with tremendous potential and if properly developed could 
provide the drugs needed to sustain our battle against drug-resistant infectious diseases in 
decades to come29.  
 
Box 5. Combination drugs, an emerging option for antibacterial therapy23.  
 
Combination of different classes of antibiotics or addition of adjuvants is a promising alternative 
therapeutic approach (Figure 6). Combination of known and effective antibiotics from the various 
classes of antibiotics can not only enhance the antibacterial activity, but can possibly also support the 
clinical development of agents previously found to be very effective but too toxic for the host. Another 
advantage is that this approach might lead to shorter and/or lower dosing regimens, which has the 
potential to reduce the rate of acquirement of resistance in pathogens. A small number of 
combination therapies have already achieved commercial success for the treatment of resistant 
infections. In fact, the best-selling antibiotic in 2001 was the two-drug combination Augmentin®, 
marketed by GSK. It is a combination of the ß-lactam antibiotic amoxicillin and an adjuvant, i.e. the 
lactamase inhibitor clavulanate. The ß-lactam targets the cell wall whereas clavulanate prevents the 
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ß-lactamase enzyme from degrading amoxicillin (mechanism 1). Bacteria become readily resistant 
against ß-lactams as the gene coding for the lactamase is abundant and easily transferred from one 
bacterial strain to another. 
 
 
 
 
Figure 6. - Mechanisms of combination therapy: (1) Adjuvant (A) inhibits the degradation or 
modification of the drug; (2) adjuvant inhibits the cell repair (a) or intrinsic resistance 
pathway (b); (3) adjuvant inhibits the efflux pumps; (4) combination of two antibiotics 
with (a) or without (b) similar target T. 
 
In addition to the synergistic effect on drug efficacy, combination therapy has the potential to slow 
the emergence of resistance. The underlying hypothesis is that treatments that inhibit multiple targets 
(on the same pathway or not) might delay and decrease the pathogen’s ability to accumulate 
simultaneous mutations that affect the multiple targets. This concept has been well documented for 
tuberculosis, malaria and leprosy.  
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Conclusions 
 
New antibiotics are badly needed to combat the growing threat of bacterial resistance.  
Despite of significant advances in bacterial genomics, high-throughput screening 
techniques and synthetic methods, discovery of novel antibiotics over the past thirty years 
has not sufficiently kept pace with the demand for new agents. Fortunately, in the recent 
years there is ample evidence that microbial natural products continue to be a rich source of 
new drugs leads. This thesis demonstrates how natural products are and could be used in a 
quest of better drugs against multi-resistant bacteria.  
 
As our battle with resistance is destined to continue, it is of utmost importance that we learn 
to use antibiotics cautiously and when appropriate. Only in this way we can delay 
dissemination of resistance, a natural phenomenon that will surely not disappear25  
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Summary 
 
Glycopeptides are fascinating molecules with a strong inhibitory activity against Gram-
positive bacteria. The two best known and today still the only glycopeptide antibiotics 
commercially available for human use are vancomycin and teicoplanin. They are often 
referred to as drugs of last resort against serious hospital infections caused by multidrug-
resistant Gram-positive pathogens, particularly methicillin-resistant Staphylococcus aureus 
(MRSA). 
 
A40926 is a prominent member of the glycopeptide antibiotic family and structurally 
related to teicoplanin. It is commercially a very important molecule as it is the precursor for 
the semi-synthesis of dalbavancin, a novel second-generation glycopeptide agent currently 
in a late stage of the clinical development for the treatment of patients infected with the 
most difficult-to-treat strains of MRSA.  
 
The multifaceted structure of A40926 makes it an ideal and at the same time challenging 
scaffold for derivatization. This, combined with an excellent activity against Gram-positive 
Staphylococcus aureus  offers a unique opportunity for the discovery and the development 
of new semisynthetic glycopeptide antibiotics.  
 
In the work describe in this thesis the selective deacylation of A40926 by immobilized cells 
of Actynoplanes teichomyceticus was investigated. By selective cleaving a fatty acid side 
chain of the molecule, a deacyl-A40926 derivative is obtained. This derivative can than 
selectively be reacylated with different acyl chains or functional groups to generate novel 
compounds. Above that, deacyl-A40926 is an indispensable element in structure-activity 
relationships (SAR) studies that are at the core of any drug development program. 
 
The main objective of this thesis research was to develop a lab-scale prototype process for 
continuous deacylation of A40926 that could produce gram quantities of deacyl-A40926, 
subsequently to be used as a precursor for chemical derivatization. This was achieved by 
implementing a continuously operated cascade of three perfectly mixed airlift loop reactors 
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(ALR) with immobilized A. teichomyceticus cells. For the design purposes effective 
diffusion coefficients of A40926 and its deacylated derivative were determined (Chapter 3) 
together with kinetic parameters (Chapter 4). That allowed us to model a process initially 
based on a single continuously operated air-lift reactor (Chapter 4). Subsequently, because 
very high overall conversion was required, a process based on a series of three ALRs was 
designed. This configuration was experimentally implemented at lab scale and operated 
continuously for two months (Chapter 5), giving a desired overall conversion of A40926 to 
deacyl-A40926 of more than 99%. Thus we demonstrated the feasibility of the continuous 
deacylation and were able to produce gram quantities of deacyl-A40926.  
 
Chemical modification, such as deacylation, of complex glycopeptide molecules is an 
almost impossible task and the solution to this should be sought in the form of biocatalysis. 
This research is a demonstration that biotransformation and bioprocess development are an 
indispensable part of a much larger process of discovering and developing new drugs. New 
and better drugs that we will continue to need in our never-ending battle against multi-
resistant bacterial infectious diseases. 
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Glycopeptiden zijn fascinerende moleculen met een sterk remmende werking op gram-
positieve bacteriën. De twee bekendste glycopeptideantibiotica – de enige antibiotica voor 
de mens die op dit moment commercieel verkrijgbaar zijn – zijn vancomycine en 
teicoplanine. Ze worden vaak gebruikt als een laatste redmiddel tegen ernstige 
ziekenhuisinfecties die worden veroorzaakt door multiresistente gram-positieve 
pathogenen, voornamelijk methicilline-resistente Staphylococcus aureus (MRSA). 
 
A40926 is een bekend glycopeptideantibioticum, dat qua structuur aan teicoplanine 
gerelateerd is. Commercieel gezien is het een zeer belangrijk molecuul omdat het de 
voorloper is van de semi-synthese van dalbavancine, een nieuw tweede generatie 
glycopeptideantibioticum dat in een laat stadium van klinische ontwikkeling is, waarmee 
patiënten kunnen worden behandeld die met de slechtst behandelbare varianten van MRSA 
zijn besmet.  
 
A40926 is met zijn veelzijdige structuur een ideale, maar tegelijkertijd lastige scaffold voor 
derivatisatie. In combinatie met een uitstekende werking tegen gram-positieve 
Staphylococcus aureus biedt dit een unieke kans om nieuwe semi-synthetische 
glycopeptideantibiotica te ontdekken en te ontwikkelen.  
 
Het onderzoek dat in deze thesis wordt beschreven, was gericht op de selectieve deacylatie 
van A40926 door geïmmobiliseerde Actynoplanes teichomyceticus-cellen. Door een 
vetzuurzijketen van het molecuul selectief af te splitsen, wordt een deacyl-A40926-derivaat 
verkregen. Dit derivaat kan dan selectief opnieuw worden geacyleerd met verschillende 
acylketens of functionele groepen om nieuwe samenstellingen te genereren. Bovendien is 
deacyl-A40926 een onmisbaar element in onderzoeken naar de structuur-activiteitsrelatie, 
die van essentieel belang zijn voor het ontwikkelen van medicijnen. 
 
Het hoofddoel van dit thesisonderzoek was om een prototype te ontwikkelen van een 
laboratoriumproces voor continue deacylatie van A40926 om gramhoeveelheden van 
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deacyl-A40926 te produceren, die vervolgens konden worden gebruikt als precursor voor 
chemische derivatisatie. Dit werd bereikt door het implementeren van drie continu 
werkende, perfect gemengde airlift loop reactors (ALR) met geïmmobiliseerde A. 
teichomyceticus-cellen. Eerst werden effectieve diffusiecoëfficiënten van A40926 en van 
het gedeacyleerde derivaat (hoofdstuk 3) en kinetische parameters (hoofdstuk 4) bepaald. 
Zo konden we een proces ontwikkelen dat in eerste instantie was gebaseerd op één continu 
werkende airlift reactor (hoofdstuk 4). Vervolgens werd er een proces op basis van drie 
ALR’s uitgedacht, omdat er een zeer hoge overall-conversie vereist was. Deze continu 
werkende opstelling werd bij wijze van experiment gedurende twee maanden in een 
laboratorium geïmplementeerd (hoofdstuk 5). Dit leidde tot een gewenste overall-conversie 
van A40926 naar deacyl-A40926 van meer dan 99%. Daaruit blijkt dat continue deacylatie 
mogelijk is en dat we in staat waren om gramhoeveelheden van deacyl-A40926 te 
produceren.  
 
Chemische modificatie, zoals deacylatie, van complexe glycopeptidemoleculen is een bijna 
onmogelijke taak en de oplossing moet worden gezocht in het gebruik van biokatalytische 
processen. Dit onderzoek toont aan dat biotransformatie en bioprocesontwikkeling 
onmisbaar zijn voor het zeer uitgebreide proces waarmee het ontdekken en ontwikkelen van 
nieuwe medicijnen gepaard gaat. Nieuwe en betere medicijnen die we voortdurend nodig 
zullen hebben in onze eindeloze strijd tegen multiresistente bacteriële infectieziekten. 
 
 
  
  
 
  
 
 
Acknowledgements 
 
 
 
 
 
  
 
Acknowledgements 
 
 
When one comes to write acknowledgments one suddenly realizes that it is not so easy to 
write such a pleasant chapter. Many memories and faces come up to the surface, and 
expressing one’s feelings and gratitude becomes quite demanding task. Nevertheless, I’ll do 
my best trying to remember everyone and to forget no one. 
 
This thesis is a fruit of quite a long process and for me personally, it is probably the most 
important professional achievement so far. During the years, many people contributed to 
this accomplishment. In the first place my parents, who were both teachers and people with 
scientific background. Particularly my father, who himself was a chemistry professor, and 
who somehow implanted in me the ambition to become ‘doktor nauka’, Serbian term for a 
PhD. During my high school and university years his influence on my intellectual 
development was quite important and brought me eventually ‘on the road of science’.  
 
However, the longest, underlying, and above all the most important support I received on 
this ‘road of science’, was in my family - my wife and my children - who gave me all of 
their love, warmth, understanding and encouragement over the years. To them goes my 
ever-lasting gratitude and affection. From my university studies in Belgrade to MSc years 
in Wageningen, and from The Netherlands to my early years in Italy they supported me all 
the way through. It is not easy to find right words to express my profound gratitude but  
Nato, Mašo i Mix, bez vas ovo sigurno nikada ne bih postigao. 
 
Yet, there is another very important, if not the most important person, whose contribution I 
very warmly acknowledge. As much as this thesis is my own achievement, it is also a result 
of the understanding and strong determination of my supervisor Hans Tramper. The man of 
aptitude and wisdom, Hans is above all, a man of great patience. Over the years we get to 
know each other well and to him I will always be very grateful. Simply: “Beste Hans, I 
would never managed without you”.  
 
147 
Acknowledgements 
The contribution of my thesis co-supervisor, Flavia Marinelli, is also warmly 
acknowledged. She was the originator of the project and articulated the idea of deacylation 
with immobilized cells. When I first came to Italy, she and her family welcomed me 
warmly and I will remember that period very gladly. Working together we had a very good 
collaboration and understanding. Her continuous support and attention was indispensable 
for the successful outcome of this research.  
 
From my early years at Lepetit Research Center, I also remember pleasant colleagues 
Angelo Borghi and Carlo Acquarella. They were always very talkative and friendly. Above 
all Marco Pedroli, at that time colleague of mine in the lab and pilot-plant and today my 
partner in our biotech company Actygea srl. With Marco I worked a lot, and not only on 
deacylation, but more importantly, we developed significant friendship. 
 
I also had a very nice collaboration with Rik Beeftink on the part of this thesis. His 
constructive criticism and very accurate observations were precious when it came to 
publishing scientific papers.  
 
Not to forget my students; Lucas de Bresser, at the time Wageningen University student, 
who spent five enjoyable months in Italy working on his thesis on continuous deacylation 
of A40926. Also Paolo Rossi, Turin University student who spent a year studying 
correlation between cell membrane fatty acids and A40926 production and with whom I 
had quite a good time in the lab.  
 
On the last published paper of this thesis I had a very pleasant and fruitful collaboration 
with prof. Giancarlo Lancini, a man who contributed to the discovery of many important 
antibiotics at Lepetit Research Center and who is the world’s authority in the field of anti-
infectives. His vast knowledge and brisk thinking were always quite stimulating. I will 
remember with the greatest pleasure our discussions at the lunch in Mensa and during 
coffee-brakes, ranging from science to ancient and modern history, from philosophy to 
politics. 
148 
Acknowledgements 
149 
Last but not least, I want to remember people that were not directly involved in this thesis 
research but were (and some still are) in and around ‘Proceskunde’ when I was there. 
People, who together with Hans make the 6th floor of ‘Biotechnion’ an extremely 
stimulating and pleasant environment for me. Renè, Kees, Joyce, Rik, Arjen, Karin, Dirk, 
Marian, Fred, you will always be a part of this memorable experience.  
 
Finally, thinking about this thesis I want to say to myself in Serbian ‘Bolje ikad nego nikad’ 
(Better ever than never), but also in Italian - Meglio tardi che mai, acknowledging this 
beautiful language and beautiful country that over the years offered me many opportunities, 
and to some extent became part of me. 
 
 

  
 
 
About the author 
 
 
 
 
 
  
 
Curriculum Vitae 
 
Srdjan Jovetić was born in Belgrade (Serbia) on 25th of August 1963. After completing his 
secondary education in 5th Belgrade Gymnasium he enrolled at Univeristy of Belgrade to 
study Food Technology. He graduated in 1989 with a thesis on wine making and in 1990 
started his postgraduate studies at the same University. Contemporarily he started his 
professional career as a research associate at  PKB INI – Agroekonomik, an R&D company 
in Belgrade. In 1990, under Scientific Cooperation Program between (at that time) 
Yugoslavia and The Netherlands, he was awarded a two-year postgraduate study grant from 
the Dutch government. With this grant he came to Wageningen in 1991 and enrolled to 
MSc course in Biotechnology at Wageningen University. He graduated in 1993 with a 
thesis on baculovirus expression vector system, a research carried out at Bioprocess 
Engineering Group. After obtaining his MSc degree he spent two years in a group of prof. 
Tramper as a research assistant working on various research projects. In 1995 he went to 
Italy as detached research associate of Wageningen University to work at MMD-Lepetit 
Research Center. The project he was involved in was in collaboration with Marrion-Merrel-
Dow and a part of this PhD thesis research was done in that period. In 1997 he moved 
definitely to Italy to continue his scientific career at Biosearch Italia S.p.A. and later on at 
Vicuron Pharmaceuticals Inc. After spending ten years in industrial R&D covering various 
positions, in 2007 he co-founded Actygea, a start-up biotech company engaged in strain 
improvement and fermentation technology development.  
 
153 

  
 
 
Bibliography 
 
 
 
 
 
  
 
Bibliography 
Jovetić, S. 1994. Natural pyrethrins and biotechnological alternatives. Biotechnology and 
Development Monitor 21, 12-13. 
Jovetić, S. and de Gooijer, C.D. 1995. The Production of Pyrethrins by in vitro Systems, 
Critical Reviews in Biotechnology, 15 (2), 125-138. 
Jovetić, S.,  Tramper, J., Marinelli, F. 1998. Biotransformation of the lypoglycopeptide 
antibiotic A40926 with immobilized cells of Actinoplanes teichomyceticus - In situ supply 
of nutrients. Enzyme and Microbial Technology, 22, 117-121. 
Jovetić, S., Beeftink, H.H., Tramper, J., Marinelli, F. 2001. Diffusion of (de)acylated 
antibiotic A40926 in alginate and carrageenan beads with or without cells and/or soybean 
meal. Enzyme and Microbial Technology, 28, 510-514. 
Butler, M.J., Bruheim, P., Jovetić, S., Marinelli, F, Postma, P., Bibb, M.J. 2002. 
Engineering of primary carbon metabolism for improved antibiotic production in 
Streptomyces lividans. Applied and Environmental Microbiology, 68 (10), 4731-4739. 
Jovetić, S., de Bresser, L., Tramper, J., Marinelli, F. 2003. Deacylation of antibiotic 
A40926 by immobilized Actinoplanes teichomyceticus in an internal-loop air-lift 
bioreactor. Enzyme and Microbial Technology, 32, 546-552  
Beltrametti, F., Lazzarini, A., Brunati, C., Marazzi, A., Jovetić, S., Selva, E., Marinelli,F. 
2003. Production and Characterization of monochlorinated and dechlorinated A40926 
derivatives. Journal of Antibiotics, 56,773-782 
M.J.Butler, E.Takano, P.Bruheim, S.Jovetić, F.Marinelli, M.J.Bibb. 2003. Deletion of scbA 
enhances antibiotic production in Streptomyces lividans 132. Applied Microbiology and 
Biotechnology, 61:512-516 
Beltrametti, F., Jovetić, S., Feroggio, M., Gastaldo, L., Selva, E., Marinelli, F. 2004 Valine 
influences production and complex composition of glycopeptide antibiotic A40926 in 
fermentation of Nonomuraea sp. ATCC 39727. Journal of Antibiotics, 57, 37-44.  
157 
Bibliography 
158 
Jovetić, S., Marinelli, F, Tramper, J.,. 2006. Continuous biotransformation of glycopeptide 
antibiotic A40926 in a cascade of three airlift bioreactors using immobilized Actinoplanes 
teichomyceticus cells. Enzyme and Microbial Technology, 38, 34-39. 
Gandolfi, R., Jovetić, S., Marinelli, F., Molinari,F. 2007 Biotransformations of 
lipoglycopeptides to obtain novel antibiotics. Journal of Antibiotics, 60(4), 265-271. 
Di Palo, S., Gandolfi, R., Jovetić, S., Marinelli, F., Romano, D., Molinari,F. 2007 A new 
bacterial mannosidase for selective modifications of ramoplanin and its derivatives. 
Enzyme and Microbial Technology, 41, 806-811 
Jovetić, S., Feroggio, M., Marinelli, F., Lancini, G.  2008 Factors influencing cell fatty acid 
composition and A40926 antibiotic complex production in Nonomuraea sp. ATCC 39727. J 
Ind Microbiol Biotechnol  35, 1131–1138 
Jovetić, S., Zhu, Y., Marinelli, F., Tramper, J.  ß-lactam and glycopeptides antibiotics – 
first and last line of defence? Submitted for publication.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cover layout design: Marija Jovetić, 2009 
 
